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Abstract
Background: The introduction of proton pump inhibitors (PPIs) into clinical practice has revolutionized the management
of acid-related diseases. Studies in primary care and emergency settings suggest that PPIs are frequently
prescribed for inappropriate indications or for indications where their use offers little benefit. Inappropriate PPI
use is a matter of great concern, especially in the elderly, who are often affected by multiple comorbidities and
are taking multiple medications, and are thus at an increased risk of long-term PPI-related adverse outcomes as
well as drug-to-drug interactions. Herein, we aim to review the current literature on PPI use and develop a position
paper addressing the benefits and potential harms of acid suppression with the purpose of providing evidence-based
guidelines on the appropriate use of these medications.
Methods: The topics, identified by a Scientific Committee, were assigned to experts selected by three Italian Scientific
Societies, who independently performed a systematic search of the relevant literature using Medline/PubMed, Embase,
and the Cochrane databases. Search outputs were distilled, paying more attention to systematic reviews and
meta-analyses (where available) representing the best evidence. The draft prepared on each topic was circulated
amongst all the members of the Scientific Committee. Each expert then provided her/his input to the writing,
suggesting changes and the inclusion of new material and/or additional relevant references. The global
recommendations were then thoroughly discussed in a specific meeting, refined with regard to both content and
wording, and approved to obtain a summary of current evidence.
Results: Twenty-five years after their introduction into clinical practice, PPIs remain the mainstay of the treatment of
acid-related diseases, where their use in gastroesophageal reflux disease, eosinophilic esophagitis, Helicobacter pylori
infection, peptic ulcer disease and bleeding as well as, and Zollinger–Ellison syndrome is appropriate. Prevention of
gastroduodenal mucosal lesions (and symptoms) in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) or
antiplatelet therapies and carrying gastrointestinal risk factors also represents an appropriate indication. On the contrary,
steroid use does not need any gastroprotection, unless combined with NSAID therapy. In dyspeptic patients with
persisting symptoms, despite successful H. pylori eradication, short-term PPI treatment could be attempted. Finally,
addition of PPIs to pancreatic enzyme replacement therapy in patients with refractory steatorrhea may be worthwhile.
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Conclusions: Overall, PPIs are irreplaceable drugs in the management of acid-related diseases. However, PPI treatment, as any
kind of drug therapy, is not without risk of adverse effects. The overall benefits of therapy and improvement in quality of life
significantly outweigh potential harms in most patients, but those without clear clinical indication are only exposed to the risks of
PPI prescription. Adhering with evidence-based guidelines represents the only rational approach to effective and safe PPI therapy.
Please see related Commentary: doi:10.1186/s12916-016-0724-1.
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Background
The introduction of proton pump inhibitors (PPIs) into
clinical practice has revolutionized the management of acid-
related diseases. Pharmacological acid suppression has been
so successful in healing peptic ulcer (PU) and managing pa-
tients with gastroesophageal reflux disease (GERD) that
elective surgery for ulcer disease has been virtually abol-
ished and anti-reflux operations are today performed only
in selected patients. Along the same lines, the incidence of
non-steroidal anti-inflammatory drug (NSAID)-associated
gastropathy has largely been reduced, despite the increased
use of these medications in the aging population [1].
Despite the fact that PPIs are far from being the ideal
antisecretory drugs [2] and that new longer-acting com-
pounds with extended acid suppression are being devel-
oped [3–5], they remain, no doubt, the most effective
currently available medications and are widely prescribed in
all age populations. Healthcare providers are increasingly
prescribing PPIs for prolonged, sometimes lifetime, use and
there is growing concern for the potential adverse effects
resulting from such long-term therapy [6, 7]. Soon after
the introduction of omeprazole, the first PPI, into the
market, Jean Paul Galmiche, a leading French gastro-
enterologist, wrote a thoughtful article [8] anticipating
that the unprecedented clinical efficacy of these drugs
would have lead (patients and physicians alike) to
addiction, and indeed, this is the case. Once on a PPI,
the majority of patients stay on long-term PPIs, often
indefinitely [9], especially the elderly [10].
Studies in primary care and emergency settings suggest
that PPIs are frequently prescribed for inappropriate indica-
tions or for indications where their use offers little benefit
[11]. Patients admitted to hospital frequently are started on
PPIs, often inappropriately [12], and these medications are
continued, following discharge, by primary care physicians.
Indeed, inadequate recommendations for PPIs in discharge
letters are quite frequent [13]. This prescription habit may
lead to a continuation of PPI therapy in primary care,
thereby unnecessarily increasing polypharmacy and the risk
of adverse events as well as burdening the public health
budget. In this connection, an Italian study [14] found that
the persistence rate of PPI therapy is fairly high, after both
appropriate and inappropriate prescriptions (62 % and 71 %,
respectively). The general practitioners’ attitude to continu-
ing or discontinuing PPIs depends on their level of know-
ledge and their perceptions of hospital physicians’
competence as well as the threshold to prescribing in hospi-
tals [15].
The introduction of generic PPIs into the market has
been followed by an increasing rate of PPI prescribing
related to chronic treatments, unlicensed indications,
and therapeutic substitutions [16]. Furthermore, since
PPIs are now available over-the-counter [17], patients
can have free access to them and for long periods of
time, without seeking medical attention [18, 19]. Coun-
seling is therefore important to ensure that patients
understand that failure of symptoms to resolve or a
rapid symptom relapse while taking a PPI is an indica-
tion to consult a physician. Furthermore, concerns about
potential masking of a more serious pathology, such as
malignancy, should not be overlooked [19].
Inappropriate PPI use is a matter of great concern, es-
pecially in the elderly, who are often affected by multiple
comorbidities and are taking multiple medications, and
are thus at an increased risk of long-term PPI-related
adverse outcomes and drug-to-drug interactions (DDIs).
There is indeed a strong relationship between the num-
ber of administered drugs and potential, clinically rele-
vant DDIs [20], particularly in older adults [21]. As a
consequence, the number of yearly papers reporting
PPI-related adverse events and/or PPI-drug interactions
has steadily increased over the past decade [22–25].
Together with inappropriate use, underuse is also
matter of concern. For instance, despite all guidelines
supporting the use of gastroprotection with PPIs in at-
risk patients treated with NSAIDs [26–28], low pre-
scription rates of gastroprotective medications have
been reported, although these rates have increased pro-
gressively (for review see [28]). In Italy, three studies
[29–31] reported a substantial misuse of gastroprotec-
tion in primary care. In particular, an underuse rate of
25 − 30 % or an overuse (young patients without any
concomitant risk factor) as high as 57.5 % were ob-
served. In addition, half PPI doses or ineffective H2-re-
ceptor antagonist (H2RA) treatment were prescribed in
another 10 % of subjects [30].
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According to the data provided by the Organization
for Economic Cooperation and Development [32], PPI
use is widespread and currently increasing, especially in
some European countries. Prescription rates have risen
substantially, not only as a consequence of the replace-
ment of H2RAs but also because of an expansion in the
overall market. PPI utilization does not appear to be
commensurate with prevalence of acid-related disease
(particularly with GERD and NSAID-gastropathy) nor
with prescribing guidelines, thus leading to significant
incremental costs to both patients and national health
systems. Inappropriate prescribing is therefore high and
costly. In a US teaching hospital, the estimated cost of
inpatient and outpatient inappropriate use of PPIs was
$12,272 and $59,272, respectively [33]. This trend is also
being observed in most industrialized countries and Italy
is no exception.
Taking all the above considerations into account, the
Italian Society of Pharmacology (SIF), the Italian Associ-
ation of Hospital Gastroenterologists (AIGO), and the
Italian Federation of General Practitioners (FIMMG)
considered it wise to review the current literature on
PPI use and to prepare a position paper addressing the
benefits and potential risks of acid suppression with the
aims of providing evidence-based guidelines for appro-
priate use of these medications.
Methods
The three scientific societies (SIF, AIGO, FIMMG), pro-
moters of the endeavor, identified experts amongst their
members in order to set-up the Scientific Committee,
who defined the methodology to be followed in the
preparation of the position paper.
The methodology adopted to process the recommen-
dations consisted of four subsequent steps. In a meeting,
held in Rome at the beginning of 2015, the Scientific
Committee identified the following 13 clinically relevant
areas on which primary care physicians and gastroenter-
ologists are uncertain about how to prescribe PPIs in pa-
tients with acid-related diseases and where drug-misuse
was found to be common:
1. GERD
2. Eosinophilic esophagitis (EoE)
3. H. pylori eradication and PU disease
4. Zollinger–Ellison syndrome (ZES)
5. Stress ulcer prophylaxis (SUP)
6. Dyspepsia
7. NSAID-associated gastrointestinal symptoms
and lesions
8. Corticosteroid use
9. Antiplatelet or anticoagulant therapy
10. PU bleeding
11. Patients with cancer
12. Cirrhosis
13. Pancreatic disease
Since PPIs are often used long-term, the benefit-to-
harm balance of such therapy was also addressed.
Each selected topic was assigned to a given expert, who
carried out an independent systematic search of the rele-
vant literature using Medline/PubMed, Embase, and the
Cochrane databases. Search outputs were distilled, paying
more attention to systematic reviews and meta-analyses
(where available) representing the best evidence.
For each topic, a draft was prepared and circulated
amongst all the members of the Scientific Committee.
Each expert then provided her/his input to the writ-
ing, suggesting changes and the inclusion of new ma-
terial and/or additional relevant references. Following
preparation of the revised draft, each topic was ad-
dressed to the Core Writing Group (CS, LG, AZ,
CB), who prepared the first draft of the full manu-
script, which was examined in Bologna on June 2015.
During the meeting, each single topic was thoroughly
discussed and each statement concerning the sum-
mary of current evidence refined with regard to both
content and wording.
The Core Writing Group then incorporated all the
suggestions raised during the Bologna meeting and pre-
pared the final draft. In doing so, an updated literature
search was performed and the most recent evidence
included. This revised document was then sent to Italian
and International experts (see Acknowledgements section)
for review. Any changes resulting from comments re-
ceived by the external experts were made on the basis of
scientific and editorial merit in order to produce the
final version of the position paper.
Results
PPIs for GERD
Summary of the current evidence
PPIs represent the mainstay of medical treatment of
esophageal manifestations of GERD; however, their bene-
fits (if any) in extra-digestive GERD are still uncertain.
Eight-week therapy with standard (once daily) dose PPIs
can achieve healing of reflux esophagitis and symptom
relief in more than 80 % of patients with typical symp-
toms. When a functional investigation is added to a
negative endoscopy in making the diagnosis, PPI efficacy
in GERD and non-erosive reflux disease (NERD) appears
comparable. Being a chronic, relapsing disease, GERD
(as well as NERD) requires long-term PPI treatment,
which can be continuous, intermittent or on-demand.
Profound and individually tailored maximal acid
suppression is needed in patients with Barrett’s
esophagus not only to control gastroesophageal reflux
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(GER) but also in the hope to achieve a chemopre-
ventive effect against neoplastic transformation.
GER (i.e., the reflux of gastric contents into the
esophagus) is a physiological phenomenon, occurring
in everybody, especially after large and fat meals. Under
physiological conditions, efficient esophageal clearing
mechanisms return most of the refluxed material to the
stomach and symptoms do not occur [34]. However,
when the reflux of gastric contents is large or aggres-
sive enough, it causes troublesome symptoms and/or
complications and adversely affects health-related qual-
ity of life, giving rise to GERD [35]. The Montreal con-
sensus subclassified the disease into esophageal and
extra-esophageal syndromes, with established or pro-
posed associations with GER [36]. Up to two-third of
patients with esophageal symptoms have a macroscop-
ically normal mucosa at endoscopy. Such patients are
usually considered to have NERD [37, 38].
GERD is primarily a motor disorder and its pathogen-
esis is multifactorial. The main motility abnormalities
include an impaired function of the lower esophageal
sphincter, an abnormal esophageal clearance and a
delayed gastric emptying in up to 40 % of cases. The
presence of hiatal hernia favors reflux, but this associ-
ation is not mandatory. The ultimate consequence of the
above motor abnormalities is the presence of acid in the
wrong place (i.e., in contact with the esophageal mucosa)
[39]. In addition, the amount of reflux increases mark-
edly after meals in both healthy subjects and in GERD
patients, an event almost exclusively due to the increase
of transient (inappropriate) lower esophageal sphincter
relaxations by food-induced gastric accommodation.
Despite the buffering content of food, the pH of the ma-
terial refluxed into the distal esophagus is acidic due to
the presence of an “acid pocket”, which occurs in both
healthy subjects and GERD patients. It represents an
area of unbuffered gastric acid that accumulates in the
proximal stomach after meals and serves as a reservoir
for acid reflux [40]. The abnormal esophageal exposure
to acid, on the other hand, is not secondary to gastric
acid hypersecretion, which has been documented in only
a small subset of GERD patients [39]. All the above
pathophysiological mechanisms are exaggerated in obese
subjects [41, 42].
Since effective drugs capable of controlling the esopha-
geal motor abnormalities are currently lacking, the
mainstay of medical treatment for GERD are antisecre-
tory drugs, which act indirectly by reducing the amount
and concentration of gastric secretion available for re-
flux, thus lessening the aggressive power of the refluxed
material [43]. PPIs also reduce the size of the acid
pocket and increase the pH (from 1 to 4) of its content
[40]. The clinical efficacy of these drugs has been clearly
shown in many studies and the superiority of PPIs over
H2RAs has been established beyond doubt [44]. The
greater pharmacodynamic effect of PPIs depends on
their ability to block the final step in the production of
acid, regardless of the secretory stimulus. Moreover, PPIs
are relatively more effective during the daytime than the
nighttime and this leads to a better control of post-
prandial reflux events [44].
Eight-week therapy with standard (once daily) dose
PPIs can achieve healing of reflux esophagitis in more
than 80 % of patients [45], a rate depending on the se-
verity of mucosal lesions [46, 47]. This healing rate can
be further improved by doubling the PPI dose [45].
Meta-analyses have shown that when compared to
omeprazole, lansoprazole and pantoprazole, esomepra-
zole achieves the highest healing rates of reflux esopha-
gitis in the short term [46, 48, 49]. The more favorable
clinical benefit of esomeprazole appears negligible in
less severe esophagitis (A & B according to the Los
Angeles classification [50, 51]), but it might be import-
ant in more severe disease [48]. Vonoprazan, a member
of the new generation reversible PPIs (called
potassium-competitive acid blockers), is able to achieve
higher intragastric pH, effectively controlling both day-
time and nighttime acid secretion [5]. As a conse-
quence, it proved to be capable of healing almost 100 %
of severe (grades C and D) esophagitis [52], a benefit
also maintained during the remission phase [53].
It is worth mentioning that currently available PPI reg-
imens do not provide the same control of intragastric
pH, evaluated both in terms of mean pH over the
24 hours and percentage of time spent at pH > 4. This
has been repeatedly demonstrated in patients with
GERD [54–56] or taking NSAIDs [57]. A large meta-
analysis [58], including 57 studies measuring intragastric
pH after different PPI regimens, found that the relative
potencies of the five compounds, compared to omepra-
zole, were 0.23, 0.90, 1.60, and 1.82 for pantoprazole,
lansoprazole, esomeprazole, and rabeprazole, respect-
ively. This lack of pharmacodynamic equivalence should
be taken into account when switching from a given PPI
to another.
PPIs are effective in obtaining symptom relief in both
erosive and non-erosive disease [59]. Their efficacy for
the relief of regurgitation is, however, modest and con-
siderably lower than that achieved for heartburn [60].
The myth that PPIs are less effective in NERD has re-
cently been dispelled by a meta-analysis [61] showing
that, when a functional investigation (pH-metry or pH-
impedance recording) is added to a negative endoscopy
to objectively confirm this condition, the estimated
complete symptom response rate after PPI therapy is
comparable to that observed in patients with erosive
disease.
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However, NERD is an umbrella term, including at least
four different patient subgroups [38], of whom only
those where acid is implicated in symptom generation
(i.e., true NERD and patients with acid hypersensitive
esophagus) are clearly responsive to PPIs [62]. This is
not the case of patients who are hypersensitive to non-
acidic reflux or those with functional heartburn. Accord-
ing to Rome IV criteria [63], both acid hypersensitive
esophagus (now called reflux hypersensitivity) and func-
tional heartburn are functional gastrointestinal (GI) disor-
ders, which should no longer be included in GERD. The
lack of abnormal acid exposure and symptom-reflux asso-
ciation makes patients with functional heartburn not
responsive to PPIs. This subgroup of subjects may benefit
from visceral analgesics (e.g., antidepressants) [64].
Although not as frequent as previously suggested, PPI-
refractory heartburn, occurring more commonly in
NERD than in erosive disease, does nevertheless exist.
Some 20 % (range 15–27 %) of correctly diagnosed and
appropriately treated patients do not respond to PPI
therapy at standard doses [65]. To ascertain whether
they are “truly” PPI-resistant, compliance and adherence
to treatment should be checked. Indeed, PPIs are often
taken inappropriately, with only 27 % of GERD patients
dosing their PPI correctly and only 12 % dosing it opti-
mally in a USA survey [66]. Although a standard PPI
dose can occasionally control symptoms, nocturnal
intragastric acidity often remains elevated (with noctur-
nal acid breakthrough, NAB) in these patients. A split
regimen (either standard or double dose) of PPIs b.i.d.
(before breakfast and before evening meal) provides
superior acid control. In patients with persistent noctur-
nal symptoms, the addition of an H2RA at bedtime may
be indicated to control NAB and associated esophageal
acidification [3, 62, 67, 68], despite the likely develop-
ment of tolerance to H2RAs [69]. The majority of pa-
tients, however, reported persistent improvement in
GERD symptoms from night-time H2RA use [67]. To re-
duce the development of tolerance, on demand or cyclic
dosing may be preferable, but this approach has not
been specifically studied.
GERD and NERD are chronic, relapsing diseases. Six
months after cessation of treatment, symptomatic re-
lapse is rapid and frequent (i.e., in 90 % of endoscopy-
positive and 75 % of endoscopy-negative patients [70]).
PPIs, both at a full and half dose, are able to maintain
patients in remission, with a superior efficacy of the full
dose (NNT = 9.1) [71]. Esomeprazole 20 mg is the only
step-down dose PPI able to maintain a significantly
higher proportion of GERD patients in symptomatic
remission, as compared to lansoprazole 15 mg [49, 72]
or pantoprazole 20 mg [49].
Since PPIs do not correct the underlying pathophysio-
logical motor abnormalities responsible for GERD, a
continuous treatment is required to maintain all patients
in remission. In the LOTUS trial [73], comparing long-
term esomeprazole therapy with anti-reflux surgery
(ARS), the estimated remission rate at 5 years was 92 %,
higher than that reported with omeprazole in the
SOPRAN study (57 %) [74]. However, while the PPI dose
in the SOPRAN trial was fixed, in the LOTUS investiga-
tion, patients whose reflux symptoms were not ad-
equately controlled by a standard maintenance regimen
(i.e., esomeprazole, 20 mg/day) were allowed to increase
the dosage to 40 mg once daily and then to 20 mg twice
daily. This dose titration may have contributed to the
improved remission rate and suggests that long-term
maintenance therapy should be individualized. Indeed,
the number and severity of relapses are highly variable
amongst patients. Infrequent reflux symptoms are less
likely to be chronic and may respond to different man-
agement strategies. There are basically three different
long-term approaches for GERD treatment with PPIs:
continuous (i.e., every day), intermittent (i.e., cycles of
daily PPI administration), or on-demand (i.e., symptom-
driven) therapy, each selected on the basis of patients’
clinical characteristics [75].
One third of patients, submitted to fundoplication, is
reported to take acid-lowering compounds (mostly PPIs)
after ARS, but only few studies have specified whether
drug use was on a regular or occasional basis [76]. A
meta-analysis of randomized controlled trials (RCTs)
[77] found that – after ARS – 14 % of patients still re-
quire antisecretory drugs. This figure increases with the
duration of follow-up and up to one third of patients
required antisecretory drugs after 10 years. The data
from non-randomized studies [78], which are higher
than the estimation provided by randomized studies (i.e.,
20 % of patients under acid suppression), are probably
more representative of the current clinical practice.
Although medication use is often considered as an
outcome measure for successful ARS, some studies
have shown that antisecretory drug use does not correl-
ate with true recurrent reflux in most patients [76] and
does not necessarily indicate a failure of the procedure.
A significant proportion of patients taking medications
after operation are using them to relieve non-reflux
symptoms and only one third of patients displays an
abnormal esophageal exposure to acid after surgery
[76]. Therefore, many patients take PPIs despite the
lack of objective evidence of GERD on esophageal testing.
The causes of persistent symptoms after surgery remain
unclear. Non-GERD symptoms might be due to increased
esophageal sensitivity while other symptoms (like bloating,
early satiety and nausea) may be unmasked when reflux
symptoms improve [79–81]. A careful selection of patients
and thorough follow-up is needed to avoid unnecessary
acid suppression in post-surgical patients.
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Before embarking on long-term treatment, an attempt
to stop acid suppression must always be considered. Of
the various interventions (patient’s education, life-style
modifications, abrupt withdrawal, and tapering), tapering
is the more effective discontinuation strategy [82].
Abrupt withdrawal might be followed by rebound acid
hypersecretion and exacerbation of symptoms [83].
Weight loss appears to be another strategy in obese/
overweight patients. Indeed, in one study, up to 54 % of
subjects compliant to a hypocaloric diet were able to
stop PPI therapy, with an additional 32 % being able to
halve the dose [84]. All the above attempts should be
considered also in patients who are already on long-
term acid suppression.
Continuous maintenance therapy is indicated in pa-
tients with Barrett’s esophagus of any mucosal length,
owing to the potential chemopreventive activity of PPIs
against neoplastic transformation, a property advocated
by the American College of Gastroenterology (ACG)
[85] and American Gastroenterological Association [86],
but denied by the British Society of Gastroenterology
guidelines [87]. Indeed, a recent meta-analysis of obser-
vational studies showed that PPI use is associated with a
71 % reduction in risk of esophageal adenocarcinoma
and/or high-grade dysplasia in this patient population
(adjusted odds ratio (OR) = 0.29) [88]. Despite a contrary
opinion of the American Gastroenterological Association
[86], current evidence suggests that standard PPI therapy
is unable to normalize esophageal exposure to acid in
the vast majority of patients with Barrett’s esophagus.
Profound and individually tailored maximal acid sup-
pression is needed not only to control GER, but also in
the hope to achieve a better chemopreventive effect [89].
In all those patients with GERD requiring long-term
PPI therapy, H. pylori should be sought and – if
present – eradicated, particularly in young patients.
This approach, recommended by international guide-
lines [90, 91], is needed to prevent the development of
atrophic gastritis or worsening of any preexisting one,
with potential for neoplastic transformation [92]. How-
ever, in accordance with the Food and Drug Adminis-
tration, ACG guidelines [93] do not recommend
routine screening for or treatment of H. pylori infec-
tion in GERD patients (strong recommendation, low
level of evidence).
Conversely from typical symptoms, the efficacy of PPIs
on extra-esophageal manifestations of GERD is uncer-
tain. This uncertainty could result, at least in part, from
the available studies, which are not homogenous, with
differences in patient selection, end-point considered,
drug used, and regimen adopted. In addition, since
extra-digestive symptoms may need higher PPI dose and
clinical improvement may take a longer time to occur,
only properly designed trials would be able to unravel a
clinical response. Unfortunately, however, this has not
always been the case.
The efficacy of PPIs in non-cardiac chest pain and
extra-digestive GERD is disappointing. In these clinical
conditions, PPIs are usually given twice daily and for ex-
tended periods (i.e., 3 or more months). However, evi-
dence is often lacking and, where available, not strong
enough to allow clear recommendations to be made.
With GERD being the most common and best-studied
cause of non-cardiac chest pain, acid suppression is the
initial pharmacological approach in this patient popula-
tion. A systematic review showed that patients with
endoscopic or pH-monitoring evidence of GERD tend to
improve, but not resolve, with PPI therapy, whereas
GERD-negative patients display little or no response
[60], a result confirmed by a more recent meta-analysis
[94]. PPIs might also improve symptoms related to atrial
fibrillation and other supraventricular arrhythmias, espe-
cially after meals, in patients with proven GERD [95].
Despite the negative conclusions of a Cochrane meta-
analysis [96], a recent review [97] suggests that a thera-
peutic benefit for acid-suppressive therapy in patients
with chronic cough cannot be dismissed, advocating a
rigorous patient selection that could allow the identifi-
cation of patient subgroups likely to be responsive. On
the contrary, no systematic reviews and meta-analyses
[98–103] found any significant clinical benefit of PPI
therapy over placebo in reflux laryngitis.
Asthma and GERD can often coexist, with reflux dis-
ease being reported in 40–80 % of patients with asthma.
While asthma medications can trigger GERD [104, 105],
PPIs might, on the contrary, improve asthma control.
Here, again, an early Cochrane review [106] showed no
benefit of PPI therapy on nocturnal symptom score and
lung function, but a recent meta-analysis [96] – by
selecting the morning peak expiratory flow rate as the
primary outcome – disclosed a benefit of PPIs over pla-
cebo, which was greater in patients with proven GERD.
Despite the widespread use of PPIs in dental practice
to manage the oral manifestations of GERD [107], treat-
ment of dental erosions represents the only objectively
documented clinical use [108].
In summary, while PPIs are the mainstay of medical
treatment for esophageal manifestations of GERD, their
benefit in extra-digestive GERD remains uncertain. The
complexity of patient presentation is matched by the
challenge in appropriate diagnosis of reflux as the cause
for patients’ symptoms, which may also be related to
other co-morbidities. Upper GI endoscopy and pH
monitoring suffer from poor sensitivity, while laryngos-
copy suffers from poor specificity in diagnosing reflux
in this group of patients [109]. An empiric trial of PPIs
could be the initial approach to diagnose and treat the
potential underlying cause of these extra-esophageal
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symptoms. For those who improve with PPIs, GERD is
presumed to be the etiology, but for those who do not
respond, diagnostic testing with impedance and/or pH
monitoring are reasonable to exclude continued acid or
weakly acid reflux. In such cases, etiologies other than
GERD may be pursued [109]. Difficult patients are best
investigated and treated in referral centers.
PPIs for eosinophilic esophagitis (EoE)
Summary of the current evidence
PPIs are considered a first-line treatment in EoE. Other
effective alternatives, such as dietary or topical cortico-
steroid therapy, should be used as second-line strategies,
owing to long-term safety concerns (topical steroid ther-
apy) and impairment of quality of life and nutritional in-
adequacy (dietary interventions). However, few data exist
to guide specific recommendations on dose and duration
of PPI initial therapy.
EoE is a chronic immune-mediated inflammatory dis-
order, defined symptomatically by esophageal dysfunction
and histologically by esophageal eosinophil-predominant
inflammation [110, 111]. Originally thought to be a rare
disease, its prevalence has greatly increased over the past
25 years. The allergic basis of EoE is supported by studies
demonstrating that the underlying etiology for EoE is
likely an aberrant “antigenic” or “immune” response, asso-
ciated with consistent clinical and histologic abnormalities
[112], and by their disappearance after antigen-free amino
acid-based elemental diet [113].
It is important to emphasize that esophageal eosino-
philia is a histological finding that requires interpretation
in the clinical context and that esophageal eosinophilia
alone does not define EoE; indeed, many other diseases
have been associated with this histologic finding [114].
Although the presence of esophageal eosinophilia was
first described in a subset of patients with GERD, it usu-
ally locates in the distal esophagus and never reaches the
high density commonly observed in EoE, where it is as-
sociated with esophageal motor dysfunction, particularly
dysphagia and food impaction [110, 111].
According to the ACG guidelines [115], PPI responsive
esophageal eosinophilia (PPI-REE) should be diagnosed
when patients have esophageal symptoms and histologic
findings of esophageal eosinophilia, but demonstrate
symptomatic and histologic response to PPIs. Originally
categorized as a distinct clinical entity, PPI-REE is now
considered a phenotype of EoE that is responsive to PPI
therapy [110]. PPIs, therefore, no longer represent a
diagnostic tool to distinguish between these two entities
characterized by esophageal eosinophilia and symptoms,
but a therapeutic option to be offered to patients with
EoE. In this clinical setting, pH monitoring does not
accurately predict response to PPI therapy [115], and
similar remission rates have been documented in pa-
tients with both normal and pathologic pH monitoring
[116]. In addition, symptom improvement is common
with PPI therapy despite persistent eosinophilic infiltra-
tion [117].
A very recent meta-analysis [116], including 33 studies
and 619 patients with EoE, found that PPI therapy led to
a clinical response in 60.8 % and histologic remission in
50.5 % of patients. However, few data exist to guide spe-
cific recommendations on dosage and duration of PPI
initial therapy. Retrospective data support the use of ei-
ther once or twice daily use, but many of the PPI-REE
studies used twice daily PPI dosing in the 20–40 mg
range of the several available PPIs [115], for which there
is a trend (albeit non-significant) towards an increased
effectiveness [116].
The reason for PPI responsiveness of this condition is
not completely understood but could be due to other,
non-antisecretory effects of PPIs [118], of which the
anti-inflammatory action [119] is the most relevant one.
In vitro and in vivo studies suggest that the anti-
inflammatory effects of PPI therapy rather than acid
suppression alone may be responsible for this improve-
ment through inhibition of the Th2-allergic pathway
[120]. Indeed, like topical corticosteroids, PPIs down-
regulated cytokine expression [121]. Alternatively, the
dilated intercellular spaces and consequent increased
mucosal permeability, present in EoE [122], may allow
allergen penetration, which triggers subsequent recruit-
ment of eosinophils to the esophageal epithelium. Some
studies have shown that dilated intercellular spaces
could recover after short-term PPI treatment in GERD
(for review see [123]), a finding recently reported in pa-
tients with PPI-REE [124].
In summary, due to their safety profile, ease of admin-
istration, and high response rates (up to 60 % clinically),
PPIs can be considered a first-line treatment for EoE.
Recent data show that patients with EoE, responsive to
topical steroids and diet, also respond to PPI treatment
[125, 126]. However, the former approaches might be set
aside as second-line, owing to long-term safety concerns
(topical corticosteroid therapy) and impairment of qual-
ity of life and/or nutritional inadequacy (dietary inter-
ventions) [115, 116, 127].
PPIs for H. pylori eradication and peptic ulcer (PU) disease
Summary of the current evidence
PPIs represent a key component of any currently adopted
regimens for H. pylori eradication. The degree and dur-
ation of acid suppression influence the eradication rate.
While almost all H. pylori-positive ulcers are cured by H.
Scarpignato et al. BMC Medicine  (2016) 14:179 Page 7 of 35
pylori eradication, H. pylori-negative and NSAID/as-
pirin-negative PUs need high dose PPIs to be healed and,
often, lifelong acid suppression is required to prevent
recurrence.
After the discovery by Warren and Marshall of the
infectious etiology of PU disease in 1984 [128, 129], sev-
eral lines of evidence confirmed that H. pylori eradica-
tion cures PU disease without the need for subsequent
long-term maintenance antisecretory therapy [130–133],
and can also be beneficial to other H. pylori-related dis-
eases [90]. While previously used only to heal PUs, PPIs
have become a key component of all the currently
adopted eradication regimens [134], thus gaining a new
role in the management of PU disease.
H. pylori is located within the gastric mucus layer,
deep within the mucus-secreting glands of the antrum,
attached to cells and even within cells, and is able to sur-
vive over a wide pH spectrum [134]. Since the survival
capabilities of H. pylori within the stomach make its
eradication difficult, several different drug combinations
have been developed, with variable and inconsistent suc-
cess, with no single therapy being effective worldwide.
Therefore, the search for a new regimen to treat H. pyl-
ori infection still continues today [135].
An effective therapy should be able to eradicate the
organism from each of these potential niches, which is
an overwhelming task for any single antibiotic, whose
in vitro susceptibility does not necessarily correlate
with successful treatment in vivo. Since the very begin-
ning, it was recognized that therapy with a single anti-
biotic leads to poor cure rates and various recipes were
attempted, resulting in several effective combinations
of antimicrobials, bismuth, and antisecretory drugs
[136].
PPIs display several pharmacological actions that give
them a place in the eradication regimens, namely:
1. They exert a direct antibacterial action against H.
pylori [137, 138];
2. By increasing intra-gastric pH, they allow the
microorganism to reach the growth phase and
become more sensitive to antibiotics such as
amoxicillin and clarithromycin [139];
3. They increase antibiotic stability [140] and
efficacy [141];
4. By reducing gastric emptying [142] and mucus
viscosity [143], they increase the gastric residence
time and mucus penetration of antimicrobials.
The mechanisms underlying the antibacterial activity
of PPIs are complex and have been detailed in a compre-
hensive review [134]. These compounds are able to bind
H. pylori cells and the bactericidal activity correlates
with the degree of binding. Electron microscopy studies
revealed – after exposure to a PPI – a significant change
in the morphology of the microorganism, with appear-
ance of coccoid forms (known to be degenerating organ-
isms) [134]. PPIs are potent inhibitors of H. pylori
urease at all pH values. This effect translates into signifi-
cant reduction of ammonia production. Since this bac-
terial metabolite is important for development of
mucosal inflammation and subsequent mucosal ulcer-
ation [144], patients receiving PPIs in combination with
antimicrobials may have the additional benefit of redu-
cing one of the potent inflammatory stimuli.
The inhibitory activity on H. pylori urease has been
confirmed in vivo. As a consequence, PPI administration
results in the inability to detect the microorganism, thus
interfering with the urease-based diagnostic tests [90,
145]. The temporary inability to detect the presence of
H. pylori is termed suppression and simply reflects a de-
crease in the number of bacteria below the limits of de-
tection [145]. It is worth mentioning that the infection
affects the degree and the duration of acid inhibition
achieved by antisecretory drugs. Amongst the mecha-
nisms by which the microorganism could modify the
pH-rising effect of PPIs, the buffering of H. pylori-gener-
ated ammonia on gastric acid remains the most convin-
cing one [69].
A large clinical trial (the MACH-2 study) clearly
showed that eradication rates achieved with two anti-
bacterial agents (clarithromycin with either amoxicillin
or metronidazole) are significantly lower than those
achieved by the same two agents, given concomitantly
with omeprazole [146]. These results were later con-
firmed by another RCT, where the combination of clari-
thromycin and tinidazole was evaluated with or without
lansoprazole [147].
PPIs now represent the key component of any cur-
rently adopted regimens for H. pylori eradication, as rec-
ommended by Italian [148] and international guidelines
[90, 149–151]. To be most effective, full dose PPIs
should be given twice daily, concomitantly with antimi-
crobials as the mean intention-to-treat cure rates are
greater in patients who use the high-dose PPI, compared
with the standard-dose regimen [152, 153].
Eradication rates achieved with standard 1-week triple
therapy (PPI-clarithromycin-amoxicillin) are dependent
on CYP2C19 genotype [154]. Therefore, although any
PPI can be selected, esomeprazole- and rabeprazole-
based eradication regimens may show a better efficacy
[155]. The biological plausibility of their superiority
over other members of the PPI-class relies on their ca-
tabolism. Indeed, esomeprazole, the S-enantiomer of
omeprazole, being - together with its metabolite (esome-
prazole sulfone) - a powerful inhibitor of CYP2C19, does
inhibit its own metabolism, rendering all subjects “slow
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metabolizers” [156]. This results in a more consistent
acid suppression and might underline the slightly
higher eradication rates reported with these PPIs [155].
Conversely from the other PPIs, the clearance of rabeprazole
is much less dependent on CYP2C19 as it is predominantly
metabolized non-enzymatically to rabeprazole thioether
[157]. As a consequence, its antisecretory effect and the
eradication rates of rabeprazole-based regimes are almost
completely independent of genetic polymorphism [158]. As
a matter of fact, a recent meta-analysis did show that, con-
trary to omeprazole and lansoprazole, the CYP2C19 geno-
type does not influence the eradication rate of
esomeprazole- and rabeprazole-based therapies [159].
The importance of profound and long-lasting acid
suppression for H. pylori eradication is illustrated by two
studies showing a significantly higher intragastric pH
and lower percent time spent at pH < 4 in patients suc-
cessfully eradicated versus those who did not get rid of
the bacterium [160, 161]. In addition, the eradication
rate was higher in NAB-negative compared to NAB-
positive patients [160]. Controlling intra-gastric acidity
is therefore needed to achieve the best eradication rates
[152, 162]. Indeed, some studies have shown that the
use of high dose PPIs might result in high eradication
rates even when one single antimicrobial agent is used
[163–165]. The recent availability of more potent and
longer-acting acid suppressants, namely vonoprazan
[5], may facilitate the use of a dual therapy (i.e., acid
suppressant plus amoxicillin) [166].
Although H. pylori infection remains the single most
common cause of PUs, an increasing proportion of pa-
tients have H. pylori-negative ulcers [167]. The propor-
tion is higher in the USA (and likely in Australia) than
elsewhere, being only 4 % in Italy [168]. Although the
precise etiology of these ulcers is unknown, some are
caused by the use of aspirin or NSAIDs [169]. Indeed,
together, H. pylori infection and NSAID use account
for approximately 90 % of PU disease [170]. Patients
with H. pylori-negative, NSAID/aspirin-negative (idio-
pathic) ulcers may have a more serious ulcer diathesis.
While NSAID ulcers can be healed with PPIs (see
below), idiopathic ulcers are likely to require long-
term management with acid-suppressing drugs. PPIs
are again the drugs of choice, although the optimal
duration of treatment is undefined and might be life-
long [171].
PPIs for Zollinger–Ellison syndrome (ZES)
Summary of the current evidence
PPIs are the drugs of choice for the medical treatment of
ZES, but relatively high doses (3–4 times the standard
dose) are required compared with those used in other
acid-related conditions. Patients with complicated ZES
(severe GERD, Billroth II resections, and multiple endo-
crine neoplasia type 1 (MEN-1) with untreated hyper-
parathyroidism) are more difficult to treat and usually
benefit from twice-a-day PPI dosing. The intravenous
route may be required initially. When curative tumor
removal is not possible, antisecretory therapy must be
continued indefinitely. Interruption of PPI treatment
can have detrimental consequences.
ZES is a rare disorder characterized by the presence
of a gastrin-producing tumor (gastrinoma), which leads
to sustained hypersecretion of gastric acid and conse-
quent PU disease (often with complications such as
perforation, bleeding, etc.), diarrhea, or malabsorption.
Gastrinomas usually develop in the non-beta islet cells
of the pancreas or in the duodenal wall (40–90 %). Up
to two-thirds are malignant. About 20–25 % of cases
are seen in patients with MEN-1 syndrome [172, 173].
Nevertheless, even rarer, ZES symptoms may arise from
a cholecystokinin-producing tumor [174], because both
cholecystokinin (CCK) and gastrin are full agonists for
the gastrin–CCK2 receptor of the parietal cell, whose
stimulation drives gastric acid secretion.
Although somatostatin analogues (octreotide or lan-
reotide) could be used to reduce serum gastrin and gas-
tric acid secretion [175–177], initial treatment is aimed
at controlling the hypersecretion of gastric acid with an
antisecretory drug. Dose titration using gastric acid ana-
lysis is the ideal way to best determine the lowest effect-
ive dose of medical therapy. Indeed, giving enough
medication just to control symptoms is not considered
adequate, and it is important that acid secretion is re-
duced below 10 mEq/h (or below 5 mEq/h in the post-
surgical stomach) to avoid ulcer recurrence and compli-
cations [178]. According to available guidelines [176,
177], a PPI is the drug of choice, but high doses (3–4
times the standard dose, once daily) are required com-
pared with those used in other acid-related disorders.
Patients with complicated ZES (severe GERD, Billroth II
resections, and MEN-1 with untreated hyperparathyroid-
ism, etc.) are more difficult to treat and may require
twice-a-day PPI dosing. The intravenous route (e.g., pan-
toprazole 80 mg every 8 hours [179]) may be required
initially. Once symptoms have been controlled, the
tumor can be investigated for surgical excision [178].
When curative removal is not possible, antisecretory
therapy must be continued indefinitely. In patients
who have undergone successful curative gastrinoma
resection, PPIs may also be required because, in more
than half of them, a hypersecretory state persists
[180]. Interruption of PPI treatment (and consequent
acid rebound) can have detrimental consequences,
including severe peptic complications (strictures, per-
forations, etc.) [181]. Patient compliance to treatment
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is, therefore, crucial and should be regularly assessed.
Over time, many patients could have the drug dose
lowered [178].
The efficacy and safety of PPIs has revolutionized the
management of ZES, so that total gastrectomy is no lon-
ger required. Long-term antisecretory treatment with
PPIs has remained effective for more than 10 years,
without development of tachyphylaxis or any dose-
related adverse effect [182]. Even at the high doses re-
quired for patients with ZES, PPIs have a notable record
of safety. An analysis of ZES patients can provide im-
portant insights into some of the safety issues, concern-
ing long-term acid suppression [183].
PPIs for stress ulcer prophylaxis (SUP)
Summary of the current evidence
PPIs are the drugs of choice for acid suppression in SUP.
The risk of bleeding in intensive care unit (ICU) is re-
duced by some 60 % in patients receiving SUP compared
with those treated with placebo or no prophylaxis. Rou-
tine prophylaxis, however, is not justified by current evi-
dence. SUP should be withheld in the majority of
hospitalized patients, unless they have multiple risk fac-
tors, since only those at risk of clinically important bleed-
ing (CIB) are most likely to benefit from preventive
strategies. Educating clinicians to follow SUP guidelines
can improve the cost-effectiveness of PPI use in this clin-
ical setting.
Stress-related mucosal disease (most commonly re-
ferred to as stress ulcer) is an acute condition that can
be detected endoscopically in the majority (75–100 %) of
critically ill patients, within 24 hours of admission to an
ICU. However, the incidence of CIB from stress ulcer in
the ICU population is low, the pooled figure from the
most recent trials being some 1 % [184]. The incidence
has improved substantially over recent decades, likely
thanks to better overall ICU care. However, the mortality
rate among patients with CIB was 48.5 %, which is signifi-
cantly higher than that (9.1 %) of those without such
bleeding [185], showing that stress-related mucosal dis-
ease can be a deadly condition.
Critically ill patients are at increased risk of develop-
ing stress-related mucosal disease and subsequent
stress-ulcer bleeding as a result of both their underlying
disease and therapeutic interventions. There are some
well-established strong, independent risk factors for
stress-related mucosal disease, respiratory failure and
coagulopathy being the most relevant ones, with an OR
of 15.6 and 4.3, respectively [184]. Other important
factors include acute renal or hepatic failure, sepsis,
hypotension, severe head or spinal cord injury, thermal
injury involving more than 35 % of the body surface
area, acute lung injury, major surgery (lasting more
than 4 hours), and history of GI bleeding [186].
Although no single study or meta-analysis has re-
ported a decrease in the overall mortality related to SUP,
guidelines from the American Society of Health-System
Pharmacists [187] and Surviving Sepsis Campaign [188]
recommend routine prophylaxis with acid suppressive
therapy for high-risk patients. The rationale for this rec-
ommendation relies on the finding that important GI
bleeding is strongly associated with prolonged ICU stay
and increased mortality [189]. Indeed, three large
meta-analyses found that the risk of bleeding in ICU is
reduced by some 60 % in patients receiving SUP com-
pared with those treated with placebo or no prophy-
laxis [190–192]. Therefore, SUP has become the
standard of care in the ICU, sometimes irrespective of
the presence of risk factors. The benefit of SUP using
real-world data is, however, not easy to estimate be-
cause of the lack of a control group.
H2RAs have also been found effective in preventing
CIB [186] and are the preferred acid lowering drugs in
some ICUs [193] despite the efficacy of PPIs being sig-
nificantly better. Over recent years, all meta-analyses
[194–197] except one [198] confirmed the superior effi-
cacy of this class of drugs. No studies showed a statisti-
cally significant difference in the rate of severe
complications, such as nosocomial pneumonia, since
these associations were not reported outcomes in any of
the RCTs assessed. A recent observational study [199]
found that PPI treatment for SUP in critically ill patients
is associated with a risk of C. difficile infection higher
than that observed with H2RAs (6.7 % vs. 1.8 %).
SUP should be withheld in the majority of hospitalized
patients, unless they have multiple risk factors [184,
186]. Indeed, as outlined by current practice guidelines
[187, 188], any risk factor different from those men-
tioned above does not independently predispose a
patient to stress ulcer bleeding. Moreover, a recent
meta-analysis suggests that patients receiving enteral nu-
trition may not require SUP [200]. On the other hand,
its implementation might be associated with an in-
creased risk of infectious complications, such as nosoco-
mial pneumonia and C. difficile-associated diarrhea.
Patients with liver cirrhosis may actually have an in-
creased mortality rate if treated with PPIs [201].
Nevertheless, several studies demonstrate that, in
many non-ICU patients lacking an indication for SUP,
acid suppressive therapy is started upon hospital ad-
mission [202]. A recent study [203], while confirming
that PPI use for SUP has spread inappropriately to
low-risk patients, found that more than 50 % of
admitted PPI users were inadvertently prescribed a
PPI at discharge, without a real medical need for acid
suppression.
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In summary, PPIs represent the drugs of choice for acid
suppression in SUP. However, routine prophylaxis is not
justified by current evidence. Only patients at risk of CIB
are likely to benefit from preventive strategies. Educating
clinicians to follow SUP guidelines can improve the cost
effectiveness of PPI use in this clinical setting.
PPIs for dyspepsia
Summary of the current evidence
PPI therapy in both uninvestigated and functional dys-
pepsia (FD) is widespread. Indeed, these drugs represent
a key component of all the currently employed H. pylori
eradication regimens. The search for and eradication of
the infection is the first line therapy in the young dyspep-
tic patient without alarm symptoms. In those patients
with persisting symptoms despite successful eradication
or naïve-uninfected patients with epigastric pain syn-
drome (EPS), short-term 4–8 week PPI treatment should
be attempted. Finally, PPI co-therapy is indicated in pa-
tients with NSAID-associated dyspepsia, also with the
aim of preventing GI events.
Dyspepsia is a common GI condition seen in clinical
practice. It is not a single disease, but rather a complex
of symptoms referable to the upper GI tract that often
overlaps with other disease entities. In front of a patient
with dyspeptic complaints, physicians should carefully
evaluate the history and perform a physical examination
in order to assume that symptoms arise from the upper
GI tract [204]. If the patient is young (< 45 years), and
there are no alarm symptoms, endoscopy and/or func-
tional investigations are usually not performed, the
condition is labeled as “uninvestigated” dyspepsia and
treatment is empiric. On the contrary, if endoscopy
does reveal a structural abnormality, management of
dyspepsia relies on treatment of the underlying disease
(e.g., PU, reflux esophagitis, or malignancy). When en-
doscopy is negative (which is the case in more than
70 % of patients with dyspeptic symptoms), FD could
be considered and, provided Rome IV criteria are ful-
filled [205], the final diagnosis can be confirmed [204].
FD is characterized by a continuous or frequently recurring
epigastric pain or discomfort centered in the upper abdomen
for which no organic cause can be determined. According to
the most updated Rome IV classification, dyspepsia is subdi-
vided into postprandial distress syndrome (PDS, including
fullness, early satiety, nausea) and epigastric pain syn-
drome (EPS, including epigastric pain or epigastric burn-
ing) [205]. However, symptom overlap with either GERD
or irritable bowel syndrome is not infrequent [206, 207].
FD is widely prevalent in the general population − up
to 15 % in Italy [208] − so that FD patients are fre-
quently managed in clinical practice by both general
practitioners and gastroenterologists. Since the etiology
of FD remains unclear and is probably heterogeneous,
no definite single treatment is currently available for
these patients [204]. Indeed, different therapeutic ap-
proaches have been proposed.
Since some drug classes (e.g., NSAIDs, calcium chan-
nel blockers, corticosteroids, ACE inhibitors, and meth-
ylxanthines) can induce dyspeptic symptoms [209], a
careful evaluation of the current drug therapy is of
paramount importance: dyspeptogenic medications
should be withdrawn whenever possible. In patients with
NSAID-associated dyspepsia, PPIs are effective and
should be given also with the aim of preventing adverse
GI events (see below).
The role of H. pylori in FD is supported by data from
meta-analyses showing that H. pylori eradication re-
sulted in a statistically significant benefit compared with
placebo (relative risk of remaining dyspeptic 0.90; NNT
= 13) [210, 211]. However, short-term benefit is often
not evident since symptom relief becomes significant
only some (up to 6) months after successful cure of
the infection [212]. Furthermore, PPIs represent a key
component of all the commonly used eradication
regimens (triple, quadruple, sequential, concomitant
or hybrid therapies).
It has been estimated that the H. pylori “test and treat”
strategy is cost-effective in those regions where preva-
lence of the infection is > 20 % [213], as in Italy, and that
the advantage persists at long-term follow-up [214, 215].
Unfortunately, no predictive factors for clinical benefit
have been identified, so that eradication treatments
should be attempted in all dyspeptic patients. H. pylori
should be investigated with either non-invasive tests or
upper endoscopy, according to the age of the patient
and the presence of alarm symptoms [148].
In patients with dyspeptic symptoms persisting des-
pite successful eradication or naïve uninfected patients
with EPS, PPI therapy can be attempted, an approach
achieving a success rate of 34 % (NNT = 10, 95 % confi-
dence interval, 7–33) [216]. PPIs are particularly effect-
ive when overlapping reflux symptoms are present,
while no significant benefit occurs in dyspeptic patients
with PDS [217]. It is worth emphasizing that the effect
of PPIs in FD occurs at standard doses and, since meta-
analyses found no dose-response effect [216, 217], es-
calating the dose in non-responders to standard doses
should not be considered. If breakthrough symptoms
occur, antacids or alginate-containing formulations may
be used [216]. Differentely from GERD, a long-term
therapy with PPIs in FD is not indicated [217]. After
successful treatment, a tapering strategy rather than
abrupt discontinuation is preferred [217]. Although
symptoms may recur in nearly 70 % of patients within
1-year follow-up [82], re-starting treatment only in
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these patients is more advantageous than a continuous
and expensive treatment, prescribed in all cases.
Dyspeptic symptoms are common in GERD patients,
especially those with frequent reflux related symptoms.
In these patients, epigastric pain, belching, bloating, and
early satiety were found to improve on PPI therapy, con-
versely from nausea and vomiting, which did not benefit
from acid suppression [218].
In addition to suppressing acid secretion, PPIs can also
inhibit gastric motility and delay emptying rate [219]
and, as a consequence, dyspeptic symptoms may actually
be worsened by PPI therapy or, alternatively, new symp-
toms (especially postprandial fullness) may arise during
treatment. If this is the case, patients could be switched
to the H2RAs, ranitidine or nizatidine, which, in addition
to their antisecretory activity, display a cholinergic-like
activity [219] and have been shown to accelerate gastric
emptying [220]. On the other hand, a Cochrane meta-
analysis [216] showed that H2RAs are better than pla-
cebo in achieving symptom relief in patients with FD.
PPIs for NSAID-associated symptoms and lesions
Summary of the current evidence
Standard dose PPIs are indicated for patients taking
non-selective NSAIDs at risk for upper GI complications
(bleeding and perforation) and for those given selective
cyclooxygenase (COX-2) inhibitors having had an episode
of previous GI bleeding. In both non-selective and COX-2
selective NSAID users, PPI therapy reduces upper GI
symptoms, in particular dyspepsia. However, NSAID-
induced adverse events in the lower GI tract are not pre-
vented by PPIs.
NSAIDs are amongst the most widely used classes of
drugs. Although they are very effective medications,
their use is associated with a broad spectrum of adverse
effects in the liver, kidney, cardiovascular (CV) system,
skin, and gut [221]. GI adverse effects are the most com-
mon and include a wide clinical spectrum ranging from
dyspepsia, heartburn, and abdominal discomfort to more
serious events such as PU with life-threatening compli-
cations, including bleeding and perforation [222].
Since symptoms are not a reliable indicator of mucosal
damage, it is important to identify factors that predict
the risk of GI events in NSAID users. The risk factors
for upper GI bleeding (UGIB) associated with NSAID
use have been well defined by several studies [222].
Among them, the most important are prior history of
complicated ulcer and age. Older age is common in
NSAID users and those aged above 65 years carry a risk
similar to those with a history of PU. Advancing age in-
creases the risk by about 4 % per year, probably because
of the presence of other associated risk factors [223].
The presence of multiple risk factors greatly increases
the risk of GI complications [222]. The role of H. pylori
infection in patients taking NSAIDs and the potential
benefit of eradication on upper GI risk in infected
NSAID users has been controversial. However, eradica-
tion of associated H. pylori infection is beneficial when
starting treatment with NSAIDs or aspirin, especially in
the presence of an ulcer history [90, 224].
An often forgotten risk factor for upper GI complica-
tions is represented by drug combinations with NSAIDs
[225]. While the role of steroids, antiplatelet drugs, and
anticoagulants is long known, the synergistic effect of
selective serotonin reuptake inhibitors (SSRIs) has until
recently been overlooked. Over the past 15 years, sev-
eral epidemiologic studies, summarized by three recent
meta-analyses [226–228], have shown an association
between SSRI use and the occurrence of UGIB, and
found that this risk is further increased among patients,
who concomitantly use NSAIDs [229, 230] and/or hold
H. pylori infection [231], while it is lowered by con-
comitant PPI intake [227, 232]. The most plausible
mechanisms underlying this detrimental effect include
a marked decrease in serotonin platelet content, with
consequent impairment of platelet aggregation in re-
sponse to injury and prolongation of bleeding time as
well as an increase in gastric acid secretion, with poten-
tial ulcerogenic activity [233, 234]. When given with
NSAIDs, SSRIs may inhibit their metabolism, raising
their blood levels and – through impairment of the
hemostasis – may promote more severe bleeding.
Since the concomitant use of both these drugs results
in a significantly higher risk of UGIB than either drug
alone [229, 230], this combination should be avoided
whenever possible and, if unavoidable, adequate gas-
troprotection should be adopted from the very begin-
ning [235].
GI symptoms usually develop within the first few days
of starting a NSAID therapy and can actually occur with
the first dose of the drug. Although some studies have
suggested that the first 2 months of treatment represent
the period of greatest risk for complications with a rela-
tive risk of 4.5 %, available evidence (from both RCTs
and observational studies) shows that the risk of GI
complications is constant over time, either during short-
term or long-term NSAID use [170]. Therefore, even a
short course of NSAID therapy (e.g., for postoperative
pain or acute musculoskeletal injury) carries a risk of GI
complications similar to that of long-term treatment. As
a consequence, prevention strategies should be imple-
mented regardless of the duration of therapy, especially
in patients with more than one risk factor (i.e., at high
GI risk).
All RCTs have shown that PPIs are more effective than
H2RAs in both preventing and treating gastroduodenal
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lesions [236]. The reasons underlying the superiority of
this class of antisecretory drugs have been clarified by pre-
clinical and clinical pharmacological studies indicating
that degree and duration of acid inhibition are both im-
portant factors in determining their efficacy in the preven-
tion of NSAID injury [237]. They also reduce upper GI
symptoms associated with both COX-2 selective and non-
selective NSAID use [236]. Due to the long half-life and
entero-hepatic circulation of several NSAIDs, a split dose
PPI might be useful; there is, however, no evidence for the
clinical usefulness of this regimen.
COX-2 selective NSAIDs (often incorrectly referred
to as coxibs1) have an improved upper GI safety pro-
file compared to traditional (non-selective) com-
pounds, as extensively shown in endoscopy and
clinical outcome studies [238–240]. The evidence is
strong, with consistent reductions in events of about
50 % in large RCTs, meta-analyses of RCTs, and large
observational studies in clinical practice [238]. Among
patients with a prior ulcer bleed, treatment with a
COX-2 inhibitor or an NSAID plus PPI is still associ-
ated with a clinically important risk of recurrent ulcer
bleed (some 10 %) [222]. In these patients, the combin-
ation of a PPI and a COX-2 inhibitor reduces the risk of
upper GI bleeding compared to that of COX-2 inhibitor
alone [28, 236]. A very recent network meta-analysis in-
deed found that this drug combination represents the best
strategy to prevent ulcer complications [241].
In addition to the upper GI tract, the NSAID-induced
damage extends beyond the duodenum. Since NSAID-
induced intestinal injury involves non-acid-related mecha-
nisms [222], co-administration of PPIs does not prevent
NSAID-induced intestinal damage but might actually
aggravate it [28, 170, 242, 243], most likely by inducing
dysbiosis [244]. Furthermore, NSAID-associated lower GI
bleeding is not prevented by PPI co-administration [245].
While the better upper GI safety of COX-2 selective
agents over traditional NSAIDs is well established, their
individual lower GI tolerability is less well evidenced and
appears to differ. Both endoscopic and video-capsule
studies have shown that celecoxib displays a better intes-
tinal tolerability compared to an NSAID plus a PPI [28].
The good upper and lower GI safety profile was con-
firmed by the large CONDOR and GI-REASONS trials
[28]. However, this benefit is partially lost when this
COX-2 selective inhibitor is combined with a PPI [243].
On the other hand, over recent years, great attention
has been focused on CV adverse effects of COX-2 select-
ive inhibitors, which prompted a re-evaluation of the CV
(and global) safety profile of traditional NSAIDs. Current
evidence suggests that non-selective and COX-2 select-
ive inhibitors display a similar incidence of these adverse
effects, but with molecule-specific quantitative differ-
ences between the various drugs [246, 247].
NSAIDs are an essential part of the therapeutic arma-
mentarium despite their well characterized GI and CV
risk profiles. Physicians should not prescribe NSAIDs
before taking a careful history and doing a physical exam-
ination so that they can acquire the information they need
to balance risks and benefits for individual patients. When
GI and/or CV risk factors are present, appropriate pre-
ventive strategies (i.e., COX-2 selective inhibitors and/or
PPI use as well low-dose aspirin) should be implemented
from the very beginning and compliance to treatment
assessed regularly, especially in the elderly [222]. Finally,
the appropriateness of an NSAID prescription should be
emphasized, i.e., to control inflammation and pain, rather
than to control pain alone [248]; only then can we hope to
limit the expanding NSAID epidemic.
PPIs for corticosteroid users
Summary of the current evidence
Corticosteroid therapy does not cause damage to the gas-
troduodenal mucosa, but can enhance the GI risk associ-
ated with NSAID use. Therefore, unless patients taking
corticosteroid therapy have a PU or are under concomi-
tant NSAID therapy, mucosal protection with a PPI is
not routinely indicated.
Contrary to NSAIDs, corticosteroids do not cause any dir-
ect injury to the gastroduodenal mucosa [249], and indeed
some experimental evidence actually suggests a mucosal
protective effect [250, 251]. These drugs may, however, in-
crease the GI risk of NSAID therapy and may hamper the
healing of idiopathic or iatrogenic ulcers [252]. The associ-
ation between corticosteroid use and GI adverse events in
patients with risk factors other than NSAID use remains
controversial. Indeed, some studies reported an increased
risk of PU complications in corticosteroid users, while other
investigators failed to demonstrate such an association
after adjustment for confounding factors [253–257]. A
meta-analysis also failed to show any significant risk for
gastric or duodenal ulcers in patients receiving cortico-
steroid treatment compared to controls [258]. It is
worthwhile emphasizing that the design of the studies
included in the meta-analysis was quite heterogeneous as
was the type of patients selected (outpatients or inpatients,
presence of comorbidity and co-therapy) as well as PU
definition. However, a systematic review of available
meta-analyses as well as of published case–control
studies reached the same conclusion [259].
A more recent systematic review and meta-analysis of
159 studies, appeared between 1983 and 2013, on GI
bleeding and perforation in corticosteroid users [260],
found that corticosteroid therapy may increase the risk
of GI events (OR = 1.43) only in hospitalized patients.
Here again, the diversity of GI bleeding definitions
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(widely varying from occult blood in stool to bleeding
requiring transfusion or hospital stay) as well as the het-
erogeneity of the patients included do not allow drawing
clinically relevant conclusions [260]. Taking these con-
siderations into account, no evidence currently supports
PPI therapy as prophylaxis for corticosteroid use in the
absence of concomitant NSAID therapy.
In summary, PPI co-therapy is not routinely indicated
in patients taking corticosteroids unless they have a his-
tory of PU or are taking NSAIDs. In hospitalized pa-
tients on corticosteroid therapy, prophylaxis against
stress ulcers could be limited to those with a history of
PU, clotting impairment or requiring mechanical venti-
lation for more than 48 hours [261]. Despite corticoste-
roids increase the risk of GI bleeding in patients with
either diverticular disease of the colon or acute ischemic
stroke [262, 263], PPI therapy is not expected to exert
any preventive effect on eventual drug-induced GI
bleeding in these patients.
PPIs in patients taking anti-platelet or anti-coagulant
therapy
Summary of the current evidence
Standard dose PPI therapy is advised for gastroprotection
in all patients on anti-platelet therapy who are at in-
creased risk of gastrointestinal bleeding (age > 65 years
or concomitant use of corticosteroids or anticoagulants or
history of PU). International Normalized Ratio monitor-
ing is required when starting or stopping PPI therapy in
vitamin K antagonist users. In patients receiving clopido-
grel or vitamin K antagonists, choosing PPI lacking inter-
ference with the hepatic CYP450 enzymes might be
preferred. No demonstrated interaction exists between
PPIs and the novel oral anticoagulants.
Based on a documented efficacy, anti-platelet therapy
(aspirin < 300 mg/daily, ticlopidine 100 mg/daily, clopi-
dogrel 75 mg/daily) is widely used for both primary
and secondary prevention of CV and cerebrovascular
ischemic events [264, 265]. However, anti-platelet
drugs may cause adverse GI events (gastroduodenal ul-
cerations/erosions, overt bleeding, occult bleeding, and
– only seldom – a perforation), with a definite prob-
ability of death, particularly in the elderly [266]. There-
fore, gastroprotection is advised in those patients at
increased GI risk during anti-platelet therapy. In-
creased risk factors include age above 65 years, concur-
rent use of steroid/anticoagulant therapy, or history of
PU [222, 255, 267–269]. Presence of relevant co-
morbidities (heart failure, renal impairment, stroke,
diabetes, on-going malignancy) and smoking are add-
itional risk factors for both GI events and related mor-
tality [255, 268–270]. Standard PPI-dose is the most
effective gastroprotective therapy [271, 272]. Regret-
tably, PPI therapy is not effective in preventing bleed-
ing lesions in either small intestine or colon induced
by anti-platelet drugs, for which no protective strat-
egies are today available [269, 273, 274].
A matter for concern is the interaction between PPIs
and clopidogrel. Based on pharmacokinetic studies, PPI
therapy reduces the efficacy of clopidogrel by interfer-
ing with the hepatic CYP2C19-based activation [275].
However, the clinical relevance of such a phenomenon
is largely controversial. Indeed, a panel of experts of the
European Society of Cardiology recently suggested that
there is no conclusive evidence to discourage PPI use
with clopidogrel due to a potential increased risk of is-
chemic events [276]. Further, the only prospective study
(the COGENT trial) demonstrated that omeprazole sig-
nificantly reduces the rate of composite GI events but
did not show any increase in the composite CV events
in patients at high CV risk [277]. Additionally, a recent
meta-analysis [278], while confirming that the pharma-
codynamic interaction between PPI and clopidogrel has
no clinical significance, actually suggests that PPIs are a
marker of increased CV risk in patients taking clopidogrel
rather than a direct cause of worse outcomes. Neverthe-
less, PPIs that lack inhibition of CYP2C19 (i.e., pantopra-
zole or rabeprazole) might be preferred in clopidogrel
users [276]. No significant interaction between PPIs and
the new antiplatelet agents (prasugrel or ticagrelor) has
been documented [276].
Co-administration of aspirin and clopidogrel is asso-
ciated with synergistic effects in causing serious GI
bleeding. Indeed, epidemiological studies have invari-
ably shown that combination of two antiplatelet drugs
produces significant excess risk of UGIB [225, 279]. PPI
co-treatment is also effective in reducing the risk of
UGIB in patients receiving dual antiplatelet therapy
[280, 281]. It is worthwhile mentioning that – among
patients with dual antiplatelet therapy and PPI co-
therapy – GI bleeding episodes are more frequent in
the lower GI tract [282]; this changing pattern of bleed-
ing likely reflects the success of gastroprotection [283].
Anticoagulants, either vitamin K antagonists or novel
oral anticoagulants, including dabigatran, rivaroxaban
and apixaban, do not cause gastroduodenal mucosa in-
jury per se. These medications may, however, facilitate
bleeding of pre-existing PUs. While gastroprotection is
generally not advised, unless a concomitant anti-platelet
or NSAID therapy is prescribed, a very recent retro-
spective cohort study found that PPI co-therapy is asso-
ciated with reduced risk of warfarin-related upper GI
bleeding. As expected, the risk reduction was greatest in
patients also taking antiplatelet drugs and/or NSAIDs,
but was still significant in those without concurrent use
of these medications [284].
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In patients under acid suppression because of gastro-
protection or any acid-related disease, intensified Inter-
national Normalized Ratio monitoring is recommended
since PPIs may potentiate vitamin K antagonist-
induced anticoagulation, most likely due to facilitated
gastric absorption of warfarin [276]. When acenocou-
marol is used as an anticoagulant, some caution is
needed when prescribing PPIs (in particular omeprazole,
esomeprazole, and lansoprazole) because of potential
DDIs [285]. No clinically significant interaction during
PPI and novel oral anticoagulant co-administration
occurs, so that dabigatran-related dyspepsia may be
safely treated with PPIs [276].
PPIs for PU bleeding
Summary of the current evidence
Endoscopy is the mainstay of treatment of PU bleeding.
However, PPI therapy – after endoscopic hemostasis – re-
duces the risk of re-bleeding, the requirement for surgery,
and mortality in high-risk patients. Pre-endoscopic ad-
ministration of a PPI can be useful in downgrading stig-
mata of recent hemorrhage, thereby reducing the need for
endoscopic hemostatic procedures.
The goal of medical therapy for bleeding ulcers has
been traditionally aimed to maintain a sustained intra-
gastric pH (> 6 units), in order to promote platelet
aggregation as well as clot formation and stability [286,
287]. Indeed, platelet function is impaired at low pH
[288], and pepsin promotes clot lysis below pH 5 [289].
Although endoscopic therapy is able to achieve
hemostasis in most patients, recurrent bleeding is not
uncommon [290, 291]. Several meta-analyses [292–294]
have shown that adjuvant treatment with a PPI after
endoscopic hemostatic therapy reduces the risk of re-
bleeding and the requirement for surgery after ulcer
bleeding but has no benefit on overall mortality, an ef-
fect seen only in Asian trials and in patients with active
bleeding or a non-bleeding visible vessel. In addition,
treatment with a PPI produces small, but potentially im-
portant, reductions in transfusion requirement and
length of hospitalization [295, 296]. Although current
guidelines [297–299] recommend a regimen of an intra-
venous (i.v.) bolus followed by a continuous infusion of
PPIs, a recent meta-analysis [300] found that the efficacy
of continuous and intermittent PPI therapies were com-
parable. Whether low-dose or oral PPIs can substitute
high-dose PPIs after endoscopic hemostasis is controver-
sial. In a recent meta-analysis from Taiwan [301], inves-
tigators concluded that low- and high-dose regimens
were equivalent. However, they included trials with a
small number of patients and patients with ulcers show-
ing low-risk stigmata or even clean-base ulcers.
Similarly, some trials [302, 303] reported that the effi-
cacy of oral PPIs is comparable to that of intravenous
PPIs, but the results were combined from open-labeled
trials with limited sample size. Furthermore, different
oral regimens were combined together and compared
with different intravenous regimens. It is also worth
mentioning that most studies included in this setting
have been performed in Asian patients [304].
Currently available PPIs are not able to maintain the
intragastric pH above 6 for prolonged periods [305]. As
a consequence, intravenous infusion has often been used
in clinical studies. Intravenous esomeprazole is faster
and more effective in raising intragastric pH than i.v.
lansoprazole [306] or i.v. pantoprazole [307–309]. Even
by the oral route, esomeprazole 40 mg, which provides
the most effective control of intragastric pH amongst
the class [54, 55], achieves greater acid inhibition than
intravenous pantoprazole (40 mg/daily) on both day 1
and day 5 [310]. The Peptic Ulcer Bleed study, involv-
ing 91 hospital emergency departments in 16 countries,
showed that high-dose intravenous esomeprazole
(80 mg, followed by 8 mg/h infusion, over 72 hours),
given after successful endoscopic therapy to patients
with high-risk stigmata of PU bleeding, reduced recur-
rent bleeding at 72 hours and had sustained clinical
benefits for up to 30 days while patients were on main-
tenance oral esomeprazole (40 mg daily) [311].
PPI treatment, initiated prior to endoscopy in patients with
upper GI bleeding, significantly reduces the proportion of
patients with stigmata of recent hemorrhage at index endos-
copy: pooled rates were 37.2 % and 46.5 %, respectively (OR
= 0.67) [312, 313]. Although there is no evidence that PPI
treatment affects clinically important outcomes (mortality,
re-bleeding, or need for surgery), pre-endoscopic (or even
pre-hospital), oral or intravenous, administration of a PPI
could downgrade high-risk stigmata of recent hemorrhage.
This might increase the success of endoscopic hemostatic
therapy and/or reduce the requirement for it.
PPIs in patients with cancer
Summary of the current evidence
In cancer patients, PPI use could be indicated to treat and/
or prevent chemotherapy-induced GERD and gastroduode-
nal ulceration, with accompanying symptoms. Patients with
GI mucositis or dysphagia might also benefit from these
drugs. Due to the low number or poor quality of the avail-
able studies, the evidence supporting these indications is low.
Amongst the adverse effects of cancer chemotherapy, GI
symptoms are the most common and have the greatest impact
on the quality of life [314–316]. Fewer than 20 % of affected
patients are referred to a GI specialist [317] since clear manage-
ment algorithms and routine referral pathways are not in place
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due to limited research in this topic. As a consequence, some
treatable symptom complexes go unrecognized and/or ineffect-
ive and potentially harmful treatments are prescribed. Some-
times, persistent symptoms do compromise or prevent
ongoing anticancer treatment.
While several guidelines for management of the GI ad-
verse effects of cancer chemotherapy do exist [318–324],
only the European Society for Medical Oncology [318]
and Multinational Association of Supportive Care in
Cancer/International Society of Oral Oncology [324]
clinical practice recommendations address gastroesopha-
geal mucositis. Different types of cancer therapy alter
the integrity of the GI mucosa [325] as well as the mi-
crobial flora that inhabit the oral cavity and the gut
[326]. These treatments also affect the amount and
composition of saliva [327]. In addition, they negatively
impact on epithelial turnover and maturation, leading
to impairment of the mucosal barrier [325]. Up to 40 %
of patients undergoing treatment with gemcitabine or
S-1 (an oral pro-drug of 5-fluorouracil) for pancreatic
cancer complained of GERD-related symptoms [328],
and endoscopy revealed the presence of severe mucosal
lesions (multiple gastric erosions, diffuse erosive gastri-
tis, gastric or duodenal ulcer) in 46 % of patients after a
single cycle of chemotherapy (with cisplatin plus etopo-
side) [329]. Gastroduodenal ulcers are extremely fre-
quent (up to 100 %) in patients submitted to hepatic
intra-arterial chemotherapy [330, 331]. Even the more
recent molecular-targeted agents are not devoid of GI ad-
verse events [332]. For instance, ulceration and perforation
of the stomach and bowel are well-known complications
of bevacizumab (a humanized monoclonal antibody
against vascular endothelial growth factor) [333, 334].
The rationale for acid suppression in patients under-
going cancer chemotherapy stems from the evidence
that cytotoxic treatment damages the gastroesophageal
mucosa, but does not affect the acid producing capacity
of parietal cells. Therefore, mucosal damage may result
– at least in part – from the effect of an aggressive
acid-peptic secretion on an already damaged mucosa
[335]. British guidelines [320] suggest PPI use –
amongst other therapeutic options – in the manage-
ment of dysphagia and/or retching induced by cancer
chemotherapy, but do not provide any indication about
the dose and treatment duration. Acid suppression ap-
pears to be beneficial in the treatment of GI mucositis
induced by chemotherapy [336] and radiation [337],
while once daily PPIs seem to improve chemotherapy-
induced GERD symptoms [328], but data are conflict-
ing. Two large clinical trials [338, 339] have shown PPIs
to be effective in the prevention of chemotherapy
(cyclophosphamide methotrexate fluorouracil or 5-
fluorouracil)-induced gastroduodenal injury and in re-
ducing the incidence of heartburn and epigastric pain.
In the more recent study [339], omeprazole was also
highly effective in preventing delays in cancer treat-
ment. No postponement of chemotherapy was required
for patients treated with PPIs, while chemotherapy was
delayed in some patients receiving placebo or an H2RA.
Several other indications for PPI use in cancer patients
have been suggested and/or proposed [340]; they include
postoperative symptom relief in patients after gastric or
esophageal resective surgery, prophylactic use in patients
treated with NSAIDs as analgesics in cancer pain, acute
management of upper GI bleeding in patients with prox-
imal GI cancer, prophylactic use in patients treated with
palliative upper GI endoscopic stenting, and prophylactic
use in cancer patients who are at high risk for PU dis-
ease. However, most of the above indications have not
been formally tested in specific, well-designed RCTs. In
addition, even for those evaluated in clinical studies (i.e.,
chemotherapy-induced GERD symptoms or gastroduo-
denal ulceration), the evidence is low and often derives
from single studies or single centers. Nevertheless, up to
73 % of patients admitted to oncology or hematology
units are treated with acid suppressants (PPIs or H2RAs)
[341, 342], mostly for SUP or unspecified gastroprotection.
The Globocan survey [343] indicates that, in 2012, ap-
proximately 32.6 million people were living with cancer
(within 5 years of diagnosis). It is therefore astonishing
and disappointing that thousands of studies, often deal-
ing with trivial GI symptoms and spending billions of
euros, have been performed while very few have evalu-
ated the potential indications of PPIs in cancer to pro-
vide physicians with the best way to cope with the GI
adverse effects of chemotherapy or radiotherapy and re-
lieve the suffering of these difficult patients.
Besides the several potential and alleged indications
of PPIs in cancer patients, increasing evidence sug-
gests, for this class of drugs, an anti-tumor effect
(through the selective induction of apoptosis as well
as an anti-inflammatory effect) [344]. They also exert
a protection of cancer cells from developing chemo-
or radiotherapeutic resistance [345]. Acidification of
the extracellular compartment represents a conceiv-
able mechanism of drug resistance in malignant cells.
In addition, it drives proliferation and promotes inva-
sion and metastasis [345]. Experimental evidence has
shown that PPIs counteract tumor acidification (via
inhibition of vacuolar H+ ATPase) and restore sensi-
tivity to anticancer drugs. Moreover, early clinical data
have supported their role as add-on medications to
anticancer treatments in patients with osteosarcoma
or breast cancer [346]. A recent large epidemiological
study (the SPORE program [347]) found that patients
with head and neck tumors, taking acid suppressants,
had significantly longer overall survival compared to
those who did not. Specifically designed clinical trials
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are ongoing to better characterize the role of PPIs as
new therapeutic agents in cancer treatment. There-
fore, at the current status of present knowledge, PPI
use as adjunct to cancer chemotherapy should not be
performed outside a clinical trial.
PPI use in cirrhosis
Summary of the current evidence
PPI use in patients with liver cirrhosis must be very cau-
tious since there is no evidence of benefit except for
downgrading esophageal ulcers after sclerotherapy or
banding of esophageal varices. There is also some evi-
dence that their use could be associated with develop-
ment of spontaneous bacterial peritonitis.
In clinical practice, PPI therapy is often used in cir-
rhotic patients, in the absence of acid-related disease, to
prevent bleeding from hypertensive gastropathy [348].
This approach is not evidence-based and therefore not
justified, also taking into account that acid secretion is
markedly reduced in these patients [349].
A systematic review, performed in 2008, was unable to
find any randomized clinical trials on acid-lowering drugs
in the prevention of esophago-gastric variceal bleeding in
cirrhotic patients. It is therefore not possible to establish
whether these drugs are beneficial or harmful in this set-
ting [350]. It is worth mentioning, however, that PPI use is
associated with a microbiota shift and functional changes
in the distal gut of patients with compensated cirrhosis, an
effect that could drive or aggravate the pre-existing small
intestine bacterial overgrowth [351, 352].
The only indication of PPIs, which is by the way weakly
evidence-based, is the prevention and/or treatment of
esophageal ulcers after sclerotherapy or variceal band
ligation. The best available evidence supports the short-term
use (maximum 10 days) of PPIs to reduce ulcer size, pro-
vided spontaneous ulcer healing is a concern. Practices such
as high dose infusion and prolonged use should be discour-
aged until evidence of benefit becomes available [353].
When prescribing PPIs to cirrhotics, the benefit-to-
harm ratio must be carefully evaluated. Indeed, PPI
therapy seems to be a risk factor for the onset of spon-
taneous bacterial peritonitis. A meta-analysis [354]
showed that, compared to cirrhotic patients not re-
ceiving PPIs, those taking these drugs had an increased
risk (N = 3815; OR = 3.15; 95 % confidence interval,
2.09 − 4.74) of developing spontaneous bacterial peri-
tonitis, an effect more evident in case–control studies
than in cohort studies [355]. Another systematic review
[356] also found an increased overall risk of bacterial infec-
tions (OR = 1.98). A more recent case–control study dis-
covered that PPI use in cirrhotic patients increases the risk
of development of hepatic encephalopathy in a dose-
dependent fashion [357]. All these analyses were mainly
based on retrospective studies. The only large, multi-
center, prospective trial [358] with PPIs dealt with
spontaneous bacterial peritonitis and found acid sup-
pression not associated with an increased risk. Fur-
ther studies are therefore needed to better clarify
these clinically relevant issues.
PPIs for pancreatic diseases
Summary of the current evidence
PPIs do not affect the clinical course of acute pancreatitis
(AP), such as the length of hospitalization and time to
starting oral intake or pain relief and, as a consequence,
they are not recommended routinely in this clinical set-
ting. However, their use – as add-on medication to en-
zyme replacement therapy (ERT) – is indicated in
patients with chronic pancreatitis (and other diseases
characterized by exocrine pancreatic insufficiency), whose
steatorrhea is refractory to ERT.
AP is one of the most common GI disorders, requiring
acute hospitalization worldwide, with a reported annual
incidence of 13–45 cases per 100,000 persons [359]. AP is
an inflammation of the pancreas; it is sometimes associ-
ated with a systemic inflammatory response that can
impair the function of other organs or systems. The in-
flammation may subside spontaneously or may progress
to necrosis of the pancreas and/or surrounding fatty
tissue. The dysfunction may resolve or may progress to
organ failure. As a consequence, there is a wide spectrum
of disease from mild, where patients recover within a few
days, to severe (10–15 %) with prolonged hospital stay, the
need for critical care support, and a 15–20 % risk of death
[360, 361]. In Italy, AP is more commonly a mild disease
with a biliary etiology and a low (5 %) overall mortality
rate [362]. Whatever the cause, it should be recognized
that AP is a systemic disease and not simply a disease of
the pancreas. Thus, this common, potentially deadly, con-
dition requires up-to-date evidence-based treatment.
AP is characterized by pancreatic and peripancreatic fat
injury in part mediated by autodigestive enzymes. Exces-
sive stimulation of the exocrine pancreas was long thought
to worsen AP [363] and this represented the rationale for
using inhibitors of exocrine pancreatic secretion (e.g.,
somatostatin and its analogs) as potential therapies for AP
[364]. Along the same lines, antisecretory agents might be
able – via inhibition of acid secretion and secretin release,
due to duodenal acidification [365] – to contribute to the
inhibition of pancreatic secretion.
Despite omeprazole being unable to inhibit amylase release
from isolated pancreatic acini [366], pantoprazole appears
capable of reducing tissue infiltration of inflammatory cells
and acinar cell necrosis in rats with experimentally-induced
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pancreatitis [367], an action likely mediated by a reduced ex-
pression of inflammatory and adhesive proteins, key media-
tors in the pathogenesis of AP. The only clinical trial to
date [368] found that treatment with pantoprazole does
not affect the clinical course of AP such as the length of
hospitalization, time to starting oral intake or pain relief.
In addition, two retrospective studies found that PPI use
does not affect clinical outcomes of patients with severe
AP [369] or prevent post- endoscopic retrograde cholan-
giopancreatography pancreatitis [370]. As a consequence,
most international guidelines on the management of AP
do not even mention PPIs. The only exception is the Ital-
ian guideline [371], which clearly states that the routine
use of PPIs is not recommended in patients with acute
AP. This guideline and a former Japanese one [372]
suggest that these drugs might be considered on a case-
to-case basis, provided that specific indications, such as
NSAID use, PU disease or bleeding, occur.
Chronic pancreatitis (CP) is a progressive, irreversible,
fibro-inflammatory disease of the pancreas, in which the
pancreatic secretory parenchyma is damaged and
replaced by fibrous tissue, resulting in morphologic
changes of the ducts and parenchyma. This process
eventually culminates in permanent impairment of exo-
crine and endocrine function of the pancreas. The clin-
ical manifestations of CP include abdominal pain as well
as steatorrhea, weight loss, and malnutrition, all result-
ing from the loss of adequate enzyme and bicarbonate
secretion [373, 374], and the so-called pancreatogenic
diabetes, arising from loss of β-cell function [375, 376].
Chronic disabling pain, which poses a major detriment
to the quality of life, is present in nearly 80–90 % of pa-
tients with CP. Although two meta-analyses found no
real benefit of ERT [377], the role of pancreatic enzymes
in mitigating abdominal pain still remains unclear and
some experts recommend a 6-week trial of non-enteric-
coated pancreatic enzymes [378].
Together with pain, most patients with advanced CP
will develop pancreatic insufficiency at some point, sec-
ondary to loss of pancreatic parenchyma. Pancreatic lip-
ase secretion is lost faster than other secretions. It is
well known that steatorrhea (due to decreased luminal
hydrolysis of dietary fat) develops only when the lipase
levels drop to less than 10 % [379]. However, this does
not minimize the importance of amylase and trypsin,
which should be an integral part of pancreatic enzyme
supplementation. Traditionally, ERT is indicated in pa-
tients with steatorrhea (fecal fat greater than 15 g/day)
and weight loss [380]. Supplemental pancreatic enzymes
alleviate diarrhea and maldigestion, associated with pan-
creatic exocrine insufficiency and also aid in maintaining
normal nutrition, thus improving the quality of life [380].
Pancreatic enzymes in tablet form are susceptible to
inactivation by stomach acid, therefore limiting their
activity in the duodenum. The secretion of bicarbonate,
which maintains an alkaline pancreatic juice, is dramat-
ically reduced in most patients [380]. In addition, during
the post-prandial period, the pH of the stomach and the
upper small intestine is significantly decreased [381].
When postprandial pH in the small intestine becomes 4
or lower, bile acids precipitate and digestive enzymes
(lipase in particular) lose their activities. Strategies to cir-
cumvent this include administering higher amounts of
pancreatic enzymes and increasing gastric pH with the
use of a PPI.
The favorable effects of antisecretory drugs on abolish-
ing steatorrhea are primarily caused by reducing acid
and volume of secretion. The end results of these actions
are to elevate the pH in the stomach and duodenum,
and facilitate the delivery and concentration of lipase in
the duodenum. Another important effect is, however,
the reduction of duodenal volume flow, which in turn
increases the concentration of intraduodenal lipolytic ac-
tivity [382]. Enteric-coated formulations protect pancre-
atic enzymes from the low pH in the stomach, allowing
enzymes to maintain their potency when they reach the
duodenum. Enteric-coated enzymes are indeed released
in the duodenum, where the pH exceeds 5.5 units. Des-
pite these formulations being resistant to breakdown by
gastric acid, some studies have shown improvements in
fat absorption when they are administered with concur-
rent acid suppression therapy [380].
The use of PPIs is recommended by international
guidelines for CP and/or pancreatic exocrine insuffi-
ciency [383–391]. The Italian guidelines [384] clearly
state that addition of PPIs is recommended only in pa-
tients with refractory steatorrhea and that acid suppres-
sion is not indicated in patients with an adequate
response to ERT. These recommendations encompass
the main diseases associated with exocrine pancreatic in-
sufficiency (like acute pancreatitis, chronic pancreatitis,
pancreatic cancer, cystic fibrosis, celiac disease, irrit-
able bowel syndrome, etc.), defined as an inadequate
pancreatic enzyme activity to digest food, generally
due to either insufficient enzyme production, insuffi-
cient enzyme activation, or to early enzyme degrad-
ation [386, 392].
Safety concerns with long-term PPI therapy
Summary of the current evidence
Being very effective and considered very safe, PPIs are often
prescribed inappropriately, especially in the elderly. The toler-
ability of PPIs is generally good, with an adverse event rate of
1–3 %. Some adverse effects are plausible and predictable;
others are idiosyncratic, unpredictable, and rare. Overall, the
benefits of PPI treatment outweigh the potential risks in most
patients, who have a relevant and appropriate indication.
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Although overuse and misuse may challenge the safety
profile, the tolerability of PPIs has been remarkably good.
Adverse events generally occur at a rate of 1–3 %, without
any significant differences among PPIs. Untoward effects
most commonly include headaches, nausea, abdominal
pain, constipation, flatulence, diarrhea, rash, and dizziness.
Long-term studies indicate a tolerability profile similar to
that found in short-term trials [22–25].
PPI-related adverse events involve the GI tract as well
as other organs and systems. The majority of these
events have been summarized in comprehensive reviews,
to which the reader is referred [393–399]. The potential
risks of long-term PPI therapy, along with the respective
evidence summary, are outlined in Tables 1 and 2.
Gastric pH is relevant for the absorption of several drugs
and its modification by antisecretory therapy may signifi-
cantly modify their pharmacokinetics [400]. PPIs also influ-
ence drug absorption and metabolism by interacting with
adenosine triphosphate-dependent P-glycoprotein (e.g., inhi-
biting digoxin efflux) or with the CYP P450 enzyme system
(e.g., decreasing simvastatin metabolism), thereby affecting
both intestinal first-pass metabolism and hepatic clearance.
A number of studies have shown that omeprazole (and, to a
lesser extent, lansoprazole) carries a considerable potential
for DDIs, since it has a high affinity for CYP2C19 and a
somewhat lower affinity for CYP3A4. In contrast, pantopra-
zole and rabeprazole display a lower potential for DDIs [401,
402]. DDIs therefore represent a molecule-related effect ra-
ther than a class-effect [403].
These interactions are clinically relevant mostly for
drugs with a narrow therapeutic index (e.g., diazepam,
warfarin, antipsychotics, etc.) [401, 404]. In addition, PPI
metabolism is very rapid in most Caucasian subjects (ex-
tensive metabolizers), so that their half-life ranges from
only 0.5 to 2.1 hours [404]. Indeed, the prevalence of
poor metabolizers, potentially at increased risk of drug
interactions, is as low as 1.2–3.8 % in Europe as com-
pared to 23 % in Asia [405]. This could explain why only
few of the reported DDIs involving PPIs have been
shown to be of clinical significance.
Recent studies have raised concerns about a possible ad-
verse interaction between clopidogrel and PPIs (currently
prescribed to patients who are receiving dual antiplatelet
therapy to prevent upper GI bleeding) that could reduce
the antithrombotic effect of the former and, therefore,
lessen protection against CV events in high-risk patients.
Table 1 Concerns about long-term therapy with proton pump inhibitors (PPIs): Digestive System
Theoretical Concern Evidence Summary
Consequences of long-term
PPI-induced hypergastrinemia
• PPI-induced hypergastrinemia is enhanced in H. pylori-infected patients [448], where the antisecretory
effect is increased
• No controlled human data support the increased risk of gastric cancer [92, 449]
• More and higher quality studies are needed to confirm or refute any causal link with gastric
cancer [450, 451]
• No data support the increased risk of colorectal cancer [452]
• An increased frequency of fundic gland (inflammatory) polyps has been reported [451, 453]
• Rebound acid hypersecretion (and increased frequency of acid-related symptoms) is
of uncertain clinical relevance [83]
• Despite unclear biological mechanism(s), two large observational studies [454, 455] reported
conflicting results concerning the putative risk of pancreatic carcinoma in PPI users
Infectious consequences of long-term
PPI-induced hypochlorhydria
• Growing evidence suggests that acid suppression increases the risk of enteric infections by
C. difficile [456–458] and other pathogens [456, 459]
• Increased Candida infections in the mouth, esophagus, stomach, and upper small intestine
of PPI users have been documented [460]
• PPI users are at increased risk of small intestinal bacterial overgrowth (SIBO) [461], while cirrhotic
patients, taking these drugs, are at higher risk of spontaneous bacterial peritonitis [354, 355]
Non-infectious consequences of
long-term PPI-induced hypochlorhydria
• According to a single case-control study [462], exposure to antisecretory drugs, including PPIs,
was associated with an increased rate of subsequent diagnosis of celiac disease, but the biological
plausibility is unclear
Dysbiosis • Dysbiosis probably represents the most consistent adverse effect of PPIs, responsible – besides enteric
infections and SIBO – for gas-related symptoms as well as aggravation of NSAID-enteropathy [463, 464]
Consequences of long-term
PPI-induced hypochlorhydria on
electrolyte and nutrient absorption
• No consistent effects on calcium or iron absorption have been reported [394, 395]
• Severe symptomatic hyponatremia has been reported as a consequence of the syndrome of inappropriate
ADH secretion [465]
• Data support an increased risk of developing significant B12 deficiency [466], but this is a clinical
concern only in elderly or malnourished patients
Idiosyncratic reactions to PPIs • Magnesium intestinal transport is inhibited by PPIs and may lead to rare but potentially life-threatening
hypo-magnesiemia [467, 468]
• Lansoprazole-induced microscopic colitis has been described [469], with complete resolution after
drug discontinuation; however, recent data suggest a class effect [470]
• Despite some case reports, epidemiological studies showing an association between PPI intake
and acute pancreatitis have given conflicting results [44]
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However, current evidence shows that, while concomitant
use of some PPIs with clopidogrel does attenuate the
antiplatelet effect of clopidogrel, this effect is unlikely to
be clinically relevant [276, 278, 406, 407]. Conversely,
denying PPIs to patients at GI risk would result in
increased life-threatening GI bleeding [277, 408, 409].
PPIs are among the most widely used prescription
drugs. Although alarms have been raised about their
long-term safety, the preponderance of the evidence
does not strongly support the concerns, publicized over
the last few years and the benefit to harm ratio remains
favorable.
The best available information on long-term safety of
PPIs derives from the SOPRAN [74] and LOTUS [73]
trials, comparing ARS with omeprazole or esomepra-
zole, respectively. Safety data were collected from pa-
tients during the 12-year period of the SOPRAN study
(n = 298) and the 5-year period of the LOTUS study
(n = 514). Serious adverse events and changes in la-
boratory parameters were analyzed. Across both stud-
ies, serious adverse events were reported at a similar
frequency in the PPI and ARS treatment groups. La-
boratory results, including routine hematology and
tests for liver enzymes, electrolytes, vitamin D, vitamin
B12, folate, and homocysteine, showed no clinically
relevant changes over time. The only expected differ-
ence concerned gastrin and chromogranin A levels,
which were elevated in the PPI group, with the great-
est increases observed in the first year [410]. Despite a
continued proliferative drive on enterochromaffin-like
cells during esomeprazole treatment, no dysplastic or
neoplastic lesions were found [411].
Based on the quality of the overall evidence, the bene-
fits of PPI treatment outweigh the potential risks in most
patients, especially if PPI use is based on a relevant and
appropriate indication [6, 44]. On the contrary, patients
treated without an appropriate therapeutic indication are
only exposed to potential risks. Because PPIs are over-
prescribed in many patients, in particular for continued
long-term use, the clinical effects should always be
reviewed and justified attempts should be made to stop
any therapy that may not be needed [397].
Table 2 Concerns about long-term therapy with proton pump inhibitors (PPIs): Extra-digestive effects
Theoretical Concern Evidence Summary
Infectious consequences of long-term
PPI-induced hypochlorhydria
• More and higher quality studies are needed to confirm or refute any causal link with
community-acquired pneumonia, especially in long-term users [471, 472]
Bone consequences of long-term
PPI therapy
• PPI use is not associated with accelerated bone mineral density loss or osteoporosis [473],
which are thought to be the underlying biological explanation for the modest
increase in the risk of bone fracture [474–476]
Dementia and Alzheimer’s disease • Although, in a mouse model, very high-dose PPI use increased the level of β-amyloid in the brain [477],
human data linking these drugs to development of dementia are conflicting [478, 479]
• The risk of development of Alzheimer’s disease in PPI users appears comparable to
that of any incident dementia [480]
Delirium • PPIs were found to be an independent factor associated with development of delirium
in geriatric inpatients [481], likely reflecting poly-pharmacy and drug-to-drug interactions (DDIs)
Acute myocardial infarction (AMI) • Since PPIs do not impair endothelial function [482], more and higher quality studies,
which have to be free from confounders [483], are needed to confirm [484, 485] or
refute [277, 278, 408] any causal link with AMI
Idiosyncratic reactions to PPIs • PPIs appear to be the most common cause of drug-induced acute interstitial nephritis (AIN).
After PPI withdrawal and corticosteroid therapy, almost all patients recovered a normal
renal function [486, 487]
• There is a small but definite increase in risk of chronic kidney disease in long-term PPI users,
likely resulting from undiagnosed or residual PPI-induced AIN [487]
• Polymyositis and other myopathies, including the life-threatening condition of rhabdomyolysis,
have been described with all PPIs [488, 489]
• Immediate and delayed hypersensitivity to PPIs, with cross reactivity amongst the members
of the class, has been described [490]
PPI-drug interactions • Acid suppression reduces absorption of levothyroxine, ketoconazole, itraconazole, atazanavir,
cefpodoxime, enoxacin, and dipyridamole while increasing that of nifedipine, digoxin,
and alendronate [400]
• Concomitant use of some PPIs with clopidogrel attenuates the antiplatelet effect of clopidogrel,
but may not be clinically relevant since there are no clinical differences in the risk for major
adverse CV events [401–403]
• Only a few drug interactions (e.g., with diazepam, warfarin, phenytoin, and methotrexate)
involving PPIs (mainly omeprazole and lansoprazole) are of clinical significance [401, 403]
• DDIs may be more frequent in some patient populations (e.g., AIDS or cancer) [403]
• The degree of DDIs associated with PPIs and the respective clinical outcomes depend on
different factors such as genotype status of CYP enzymes, ethnicity, and drug regimen [403–405]
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Discussion
PPIs remain the leading evidence-based therapy for acid-
related diseases, including GERD, PU disease, dyspepsia,
NSAID-induced ulcer, H. pylori infection, and hyperse-
cretory disorders such as ZES [1, 3, 4, 412, 413].
The strong evidence supporting PPI efficacy and a fa-
vorable safety profile has led to overuse of these drugs
in many treatment arenas [11]. Surprisingly, despite
more than 25 years of extensive literature addressing
PPI therapy in upper GI disorders, inappropriate use
remains consistently high both in hospital and in pri-
mary care [7]. In a recent US study [414], only 39 % of
inpatients’ prescriptions were compliant to guidelines,
with a difference between academic and non-academic
hospitals (compliance being 50 % vs. 29 %, respectively).
Prophylaxis of upper GI bleeding in low risk patients
was the most common indication for non-compliant
prescriptions, while that of guideline compliant pre-
scriptions was treatment of dyspepsia [414].
The questionable and inappropriate PPI use in the
absence of documented evidence, supporting clear indi-
cations, is likely due to the perception that many physi-
cians have about PPI safety, which makes them forget
to assess the harms and benefits of (especially long-
term) therapy [415]. Several studies (for a review see
[11]) have shown that physicians frequently do not re-
view and document PPI indications, which often results
in their long-term or even indefinite continuation.
There are two main concerns pertaining to PPI over-
use and misuse: drug expenditure, which has risen dra-
matically in recent years, even after the introduction of
cheaper generic formulations [416], and growing safety
concerns [393–399, 417]. Despite their concentration
within the secretory canaliculi of the parietal cell and
their pharmacologic selectivity [418], PPIs also have a
“dark side” [419]. Sir William Osler once famously com-
mented that no drug has a single effect and these sec-
ondary actions range from mildly inconvenient to
frankly dangerous [420] – PPIs are no exception.
Non-judicious PPI use is a matter of great concern in
the elderly, who often have multiple comorbidities, are
taking multiple medications, and are thus at increased risk
of long-term PPI-related adverse outcomes. PPI-related
adverse events involve the GI tract as well as other organs
and systems. The potential risks of long-term PPI therapy,
along with the respective evidence summary, have been
summarized in the Safety section. While some concerns
about the possible adverse effects of PPIs (including an in-
creased risk of gastric carcinoids, gastric carcinoma, de-
creased absorption of minerals and vitamins) have been
raised since their introduction in the late 1980s, more re-
cently, the number of publications dealing with PPI-
related adverse outcomes has steadily increased [393–398,
417]. It is worth mentioning, however, that the majority of
studies are observational in nature and do not allow for
establishing causality, but merely associations [421]. Re-
sidual bias is always a concern in observational studies,
even after statistical adjustment, because all confounding
factors cannot be recorded or even known. When effect
sizes are small (relative risk/OR/hazard ratio < 2), it is not
possible to determine whether the association is valid or
represents the result of residual bias [422]. Hazard ratios for
PPI use and some reported adverse effects (e.g., dementia,
chronic kidney disease, any fracture, or community-
acquired pneumonia) were all ≤ 1.5. Nevertheless, if a true
causality exists, even small effect sizes can result in a mean-
ingful risk for common interventions and conditions.
Despite PPIs carrying – like any other classes of drugs
– some risks, they should not be denied to patients who
are likely to benefit from them merely because of con-
cerns about putative adverse effects. There is generally
some equivalence between the acceptable burden of ad-
verse effects and the severity of the illness being treated
[420]. However, patients with acid-related diseases are
often otherwise “healthy” subjects, who take drugs for a
given condition. What level of undesirable effects would
be acceptable for them and who will bear the cost of
treating any ensuing iatrogenic disease? A number of
simple and potentially effective preventive measures
should be recommended for some (if not all) safety con-
cerns in order to minimize them.
First of all, PPI therapy should be evidence based. Deci-
sions on whether or not to initiate or continue PPI therapy
should be sound and PPIs should only be prescribed when
there is an appropriate clinical indication. Clinical guidelines
can certainly help. In this Position Paper, we have reviewed
the current available guidelines, together with the systematic
reviews and meta-analyses used to generate them, and
synthesized the knowledge in a number of statements
(i.e., Summaries of the current evidence) and in Table 3.
Guidelines rely on both evidence and expert opinion;
they are neither infallible nor a substitute for clinical
judgment. They do, however, go beyond systematic
reviews to recommend what should and should not be
done in specific clinical circumstances. Despite guide-
lines being developed to improve quality of care
received by patients, they have been criticized for
recommending too little or too much, and even for pro-
viding reasons for national health systems or insurance
payers to deny coverage [423]. Guidelines are often in-
flexible and can actually harm by leaving insufficient
room for clinicians to tailor care to individual patient
circumstances and medical history. What is best for pa-
tients overall, as recommended by guidelines, may be
inappropriate for individuals [424]. Only evidence-
based recommendations, which consider the balance
between benefits and harms, and weigh these consider-
ations using patient (rather than expert and societal)
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value, should be followed in everyday clinical practice.
Taking these considerations into account, we have tried
to distill the current evidence and provide physicians
with clear patient-oriented recommendations, beyond
cost and reimbursement issues. Medicine is a rapidly
evolving field, however, and the validity of guidelines
will not necessarily stand the test of time: indeed, to-
day’s assumptions may no longer be valid tomorrow.
Healthcare providers should therefore stay tuned and
constantly update their knowledge.
PPIs continue to be prescribed outside treatment
guidelines. In Europe, the most common inappropriate
use of PPI is for the prevention of gastric damage in co-
therapy with agents that have a low gastrotoxicity, if any,
or in patients without GI risk factors for significant gas-
troduodenal damage [30, 31, 425–427] as well as in the
prevention of stress-induced bleeding [14, 428–430].
PPIs are often started as an inpatient treatment and con-
tinued (often long-term) on discharge for non-indicated
reasons [14, 431, 432].
PPIs are now available – at half the prescription dose –
as over-the-counter (OTC) medications, i.e., they can be
purchased directly without prescription. Although the
proportion of patients taking OTC PPIs internationally is
unknown, it may well represent the majority of use glo-
bally. A recent US survey [433] found that 32 % of patients
Table 3 Current indications of proton pump inhibitor (PPI) therapy
Clinical setting PPI dose and duration
GERD
Erosive Esophagitis (A/B) Standard dose PPI therapy for 8-12 weeks
Erosive Esophagitis (C/D) Double dose PPI therapy for 8-12 weeks
NERD Standard dose PPI therapy for 4-8 weeks
Long-term Management (both GERD and NERD) Standard (or half) dose PPI maintenance (continuous, intermittent or on-demand,
depending on clinical characteristics of the patient)
Barrett’s Esophagus Long-term individually-tailored PPI therapy
Extra-digestive GERD Standard or double-dose PPI therapy for at least 12 weeks
Eosinophilic Esophagitis Standard or double dose PPI therapy for 8-12 weeks
H. pylori Eradication Double dose, twice daily, PPI therapy for 7-14 days (in combination with antimicrobials)
Non H. pylori-related PU disease Standard dose PPI therapy for 4-8 weeks
Zollinger-Ellison Syndrome High-dose (eventually twice daily) long-term PPI therapy
Stress Ulcer Prophylaxis
in patients with risk factors
Standard PPI therapy by intravenous route only during ICU stay
Dyspepsia
Uninvestigated Dyspepsia in Patients younger
than 45 yrs
Standard or half-dose empiric PPI therapy for 4 weeks
Functional Dyspepsia (EPS phenotype) Standard or half dose PPI therapy for 4-8 weeks
NSAID-gastropathy
Prevention of gastro-duodenal lesions and
events
Standard or half-dose PPI therapy, starting form the very first dose of NSAID in
patients at GI risk
Treatment of gastro-duodenal lesions Standard dose PPI therapy for 8 weeks
Steroid therapy No need for gastroprotection unless used in combination with NSAIDs
Anti-Platelet Therapy Standard dose PPI therapy, starting form the very first dose of antiplatelet agent
in patients at GI risk
Anti-Coagulant Therapy No need for gastroprotection unless used in combination with antiplatelet therapy
PU Bleeding Intravenous bolus of 80 mg of the available injectable PPIs, followed by 8 mg/h for 72 hours
Cirrhosis
Hypertensive gastropathy No need for acid suppression
Prevention or/and treatment of esophageal ulcers
after sclerotherapy or variceal band ligation
Standard dose PPI therapy for 10 days (longer treatment should be avoided taking
into account the risk of spontaneous bacterial peritonitis)
Pancreatic Diseases
Acute pancreatitis No benefits from acid suppression
Chronic pancreatitis Standard PPI therapy only in patients with steatorrhea, refractory to enzyme
replacement therapy
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with GERD symptoms were using OTC PPIs, with only
39 % of consumers using them optimally, with better
symptom relief. Besides patients, 50 % of US gastroenter-
ologists also use (i.e., suggest to patients) OTC PPIs [434].
Despite the vast majority of them (76 %) feeling that OTC
brand name and generic formulations were equally effect-
ive (which is not always the case [435]), the majority of
them recommended the brand medication [434].
The availability of OTC PPIs provides consumers with
options other than antacids and H2RAs for self-
medication of acid-related symptoms. Prospective clin-
ical trials have shown the efficacy of these drugs taken
on demand or intermittently on GERD management,
with potential for cost reduction [17]. Although guide-
lines for OTC use [18, 436] suggest a short course
(2 week treatment) of PPIs in patients with typical com-
plaints (acid and/or regurgitation), and without alarm
symptoms, great potential for misuse and/or overuse does
exist. Major concerns include management of patients in
whom symptoms persist despite acid suppression, appro-
priate administration, and the potential masking for more
serious pathology, like malignancy. Therefore, guidelines
and position statements are not just for specialists and
general practitioners but should be extended to clinical
and community pharmacists as well as to patients.
PPIs are among the safest class of drugs. Although
concerns have been raised on their long-term safety, the
preponderance of evidence does not strongly support
the concerns, publicized over the last few years, and the
absolute risk is probably low. Some adverse effects are
plausible and predictable; others are idiosyncratic, un-
predictable, and rare. Based on the quality of the existing
evidence, the benefits of PPI treatment outweigh the po-
tential risks in most patients, especially if PPI use is
based on a relevant and appropriate indication [6, 44].
Conversely, patients treated without an appropriate
therapeutic indication are only exposed to potential risks
and the benefit-to-harm balance becomes very low. Con-
sequently, the overall focus should be on the appropri-
ateness of PPI therapy and on a regular assessment of
the need for continued PPI treatment.
Nearly all the adverse outcomes associated with PPIs
occur among patients who receive long-term therapy;
minimizing the duration of treatment by periodically
reviewing a patient’s need for acid-suppressive therapy
could eliminate or substantially reduce the risk of adverse
outcomes. Therefore, during continued long-term use, the
clinical effects should always be reviewed and attempts be
made to stop any therapy that may not be needed [397]. It
is imperative to use the lowest dose of drug required to
achieve the desired therapeutic goals. This may entail
implementing discontinuation of treatment in asymptom-
atic patients as well as step-down [437, 438], intermittent
[437, 439, 440], or on-demand PPI therapy [440–442] for
maintenance of GERD. It should be emphasized, however,
that PPI treatment in GERD is merely palliative in nature,
since it does not address the underlying pathophysiology,
something only ARS is able to achieve [443–445]. There-
fore, in young fit patients needing continuous acid
suppression, fundoplication should be considered. Inter-
mittent or on-demand PPI therapy is not suitable for
NSAID users, since the risk of serious GI events is con-
stant in those patients with GI risk factors and can persist
for some time after stopping therapy [170, 222].
Under the current situation of PPI misuse, opportun-
ities do exist to increase appropriateness in order to en-
hance effectiveness and safety of drug therapy as well as
minimize overall healthcare costs. As always, educa-
tion is the key [7, 491]. Issuing guidelines and imple-
menting them represent the most rational approach
to the problem. Judicious surveillance of hospital use
and prescription refills in the outpatient settings
[416], with re-evaluation and justification for contin-
ued treatment, can minimize the potential for adverse
effects and achieve cost saving. However, surveillance
must be close and continuous since the attained bene-
fits could be short lasting. Indeed, in a recent Canad-
ian study [446], de-prescribing guidelines were
associated with a decline in PPI use during the initial
6 months, but prescription patterns began to climb
back to baseline afterwards.
Conclusions
Overall, PPIs are irreplaceable drugs in the management
of acid-related diseases. However, PPI treatment – as any
kind of drug therapy – is not without risk of adverse ef-
fects. The overall benefits of therapy and improvement in
quality of life significantly outweigh potential risks in most
patients, but those without clear clinical indication are
only exposed to the risks of PPI prescription. Adhering to
evidence-based guidelines represents the only rational ap-
proach to an effective and safe PPI therapy.
Endnotes
1The term “coxib” is being used in the medical/scientific
literature as synonymous of “selective COX-2 inhibitor”,
which is not the case. The term “coxib” is a World Health
Organization term used to describe a chemical class. It
does not describe any pharmacological activity, nor
indicate anything regarding COX-2 selectivity. Actually,
there are members of the coxib family (e.g., SC-560)
that selectively inhibit COX-1 [447].
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